Table Of Content

Gotschall RR, 24 Hust R, 1002 Knebel N, 175 Martin B, 7S Grafe E-U, 731 Knupp C, 419, 791 Martin BR, 20S Graham S, 558 Igel M, 835 Kohlert C, 731 Martin JM, 1147 Granneman GR, 540 Ikura-Morii M, 1275 Kohno K-l, 782 Martin PD, 1116, 1352 Grant EM, 928 Imano H, 806 Komamura K, 342 Martinez MN, 620 Grant I, 48S Innocencion G, 267 Kondo T, 1083, 1335 Martinez-Tobed A, 1303 Greenblatt DJ, 376, 1142, 1269 Inoue Y, 1083 Konsil J, 52 Marz RW, 731 Greenhalgh C, 520 Ishii Y, 1020 Koren G, Matsuda K, 151 Gross J, 403 Iyer GR, 428 Korn SH, 61 Matsuki S, 1020, 1159 Gruber AJ, 41S Kornhauser D, 1326 Matsumoto K, 342 Guan X, 899 Jaber LA, 89, 1299 Kornhauser DM, 738 Matsumoto N, 151 Gupta SK, 1109 Jacobs S, 1109 Kotegawa T, 183, 1159 Matsuno H, 782 Gutierrez M, 157 Jaehde U, 762 Kourides I, 651 McCauley J, 798 Guzzo CA, 1122 Jahnchen E, 1257 Kovarik JM, 95, 222 McCune JM, 82S Jain A, 798 Kozawa O, 782 McLeod HL, 412 Hajda JP, 1257 James GC, 528 Krahmer N, 920 McMasters K, 774 Hampel F Jr, 1097 Jann MW, 1165 Krzyzanski W, 501 Mechoulam R, 11S Haney M, 34S Jansat JM, 1303 Kulawy , 376 Medve R, 24 Harari D, 1134 Janssens L, 1341 Kuranari M, 1159 Mehlisch DR, 904 Hardman T, 1358 Jasti BR, 327 Kuroda T, 81 Merz M, 312 Hardman TC, 887 Jayawardena S, 912 Kurokawa N, 1374 Messig M, 651 Harmatz JS, 1142 Jenkins JM, 887 Kutz K, 283 Metz DC, 512 Harris SC, 520 Jenkins VC, 528 Kuwahara S, 806 Meyerrose GE, 1187 Harrison F, 605 Jesussek B, 1262 Kuye O, 444 Middleton M, 774 Harrison LI, 1134 Johnson FK, 1089 Mihara K, 1083, 1335 Hartman R, 558 Jones RT, 58S Lane A, 1147 Milton KA, 528 Hartmann S, 222 Junge K, 995 Lantz MV, 304 Mirani A, 644 Hashibe M, 103S Jusko WJ, 501 Lasseter KC, 1122, 1341 Miyamoto G, 492, 1318 Hashiguchi M, 151 Lathers CM, 7, 123, 477, 587, 718, 846 Miyatake K, 342 Hashimoto H, 1275 Kaido M, 1374 Lau CBS, 30 Moller-Pedersen J, 1262 Hashimoto H, 342 Kalbag J, 95 Lau H, 1341 Mondick J, 1326 Hatzelmann A, 297 Kamakura S, 342 Laurent A, 774 Mondick JT, 738 Hebert SJ, 82S Kanamaru M, 782 Lazarus HM, 395 Money D, 267 Hein DW, 613 Kaneko S, 1083, 1335 Leclerc V, 297 Moore BA, 28S Hejmanowski LG, 461 Kanitra L, 1011 Leeder JS, 24 Moore R, 1011 Heller HJ, 1251 Karafilidis J, 662 Lefévre G, 1147 Morganroth J, 520, 558 Hellriegel ET, 205, 450 Kashuba ADM, 376, 1079 Lehtonen L, 43 Morimoto T, 183, 1159 Hermann R, 995 Katneni K, 670 Leung A, 70 Morisaki T, 1374 Herrera P, 870 Kato H, 782 Levine M, 475 Moriya M, 1374 Herrlinger C, 985 Kato R, 1275 Levine RA, 676 Muder RR, 644 Higuchi S, 81 Kato R, 806 Liao S, 24 Mullangi R, 670 Higuera-Alhino D, 82S Kaul S, 419, 791 Lichtman AH, 20S Miiller M, 403 Hino F, 151 Kawabata Y, 782 Lim J, 1097 Mulligan TE, 1011 Hirose Y, 183 Kawai M, 1275 Liston HL, 104 Muraguchi R, 1020 Ho SSS, 976 Kawai M, 806 Loebstein R, 267 Murthy BP, 569 Ho T, 267 Kearns GL, 24, 1089 LoRusso P, 1228 Hochhaus G, 662 Kemp J, 1352 Lukacsko P, 198 Nafziger AN, 376, 1079 Holmes GB, 1089 Kemp JV, 1244 Lynch JP, 899 Nagashima S, 782 Hon YY, 1165 Kenney KB, 887 Naidu MUR, 670 Hoshaw-Woodard S, 1171 Khalsa KH, 7S Ma MK, 412 Nairn K, 1237 Hosogai Y, 151 Kim JS, 376 Ma P, 1228 Nairn K, 1244 Houle J-M, 547 King JD, 61 Ma S, 738, 1326 Nakagawa M, 1020 Hsieh JY-K, 1122 Kitani M, 492, 1318 MacArthur RD, 613 Nakamura H, 275 Huang F, 1002, 1341 Kivikko M, 43 Madani S, 1211 Nakamura K, 1020 Hubert M, 222 Klecker RW Jr, 971 Manowitz N, 1089 Nakano S, 183, 1020, 1159 Hudson JI, 41S Klein A, 1142 Marbury TC, 1109, 1311 Nakatsuka K, 1020 Huestis MA, 41S Kloft C, 762 Marcello SR, 388 Naredi P, 774 Hunt TR, 215 Klotz U, 985 Markowitz JS, 104 Nava-Ocampo AA, 37 Nelson HS, 319 Poondru S, 327 Schneck DW, 1116, 1352 Swift R, 1228 Nelson M, 205, 450 Pope HG Jr, 41S Schneider E, 995 Sy SKB, 738 Neuhauser M, 297 Porras AG, 215, 1122 Schneider W, 222 Szyjkowski RS, 676 Neuhofel AL, 461 Preston RA, 754 Schnell D, 388 Newman KB, 319 Prince WT, 887 Schraeder PL, 123 Tachibana M, 342 Nichol JM, 501 Pritchett ELC, 388 Schran H, 1228 Takahashi K, 1374 Nichola P, 419 Pruchnicki MC, 1171 Schulte MC, 388 Takahata T, 1335 Nicolau DP, 928 Schulteis G, 70 Tammara B, 492, 1318 Niecestro R, 198 Quinn J, 711 Schwartz JI, 215 Tanaka K, 1275 Nightingale C, 928 Quintiliani R, 928 Schweer H, 985 Tanaka K, 342, 806 Nishida Y, 1374 Quon CY, 1326 Schwertschlag US, 157 Tanaka T, 151 Niwa M, 782 Sciberras DG, 1122 Tashkin DP, 71S Nonaka T, 81 RaffH , 319 Scott NR, 528 Tateishi T, 100, 1335 Noveck R, 1027 Rajagopalan R, 670 Seaber E, 1237 Thomann P, 1262 Nowak SN, 89, 1299 Rance DJ, 528 Seaman J, 1228 Thomasson HR, 1219 Nwose OM, 1116 Rani UP, 670 SenderovitzT , 1262 Thyroff-Friesinger U, 403 Rao MNVS, 670 Seyberth HW, 985 Timmer W, 297 O'Day S, 774 Raoult A, 1002 Shade SB, 82S Tipping R, 1122 O’Mara E, 419 Rasty S, 577, 1366 Shader RI, 1142 Tisdale JE, 577, 1366 O’Neil WM, 613 Rauch C, 1311 Shah AK, 520 Tishler CL, 365 Ochs HR, 1142 Ravera C, 1228 Shahinfar S, 870 Tobillo E, 1109 Ohdo S, 81 Ravikanth B, 670 Shapiro R, 798 Tracey JB, 881 Ohno K, 151 Reed MD, 275 Sharma ND, 577 Trang JM, 492, 1318 Ohno M, 1374 Rehak E, 403 Shaw LM, 166 Trenk D, 1257 Ohtani Y, 183 Remple V, 267 Shaw W, 870 Troy S, 175 Ohtsuji M, 151 Richards L, 175 Shelley S, 1358 Triiten VDJ, 1142 Qie S, 1257 Ridgeway B III, 70 Shen J, 198 Truyen L, 428 Olubodun JO, 1142 Rikihisa T, 151 Shilstone J, 662 Tsikouris JP, 1187 Ono S, 1335 Rinder HM, 881 Sidney S, 64S Tsuchishita Y, 1275 Ooi K, 1275 Risch SC, 104 Siegert W, 762 Tsuchishita Y, 806 Otani Y, 1159 Robertson P Jr, 205, 450 Skerjanec A, 1228 Tsunoda SM, 376 Rocci ML Jr, 376, 1079 Slaughter RR, 89 Tsutsumi K, 183, 1159 Padhi ID, 577 Rogers JF, 1079 Smith BP, 1219 Turner M, 1165 Page RL, 388 Rohatagi SS, 1097 Smith CM, 477 Turner MB, 512 Pallotta T, 904 Romero A, 395 Smith JA, 867 Parasrampuria DA, 304 Rordorf C, 95, 222 Smith PF, 658 Uejima E, 1374 Park Y, 157 Rosenkranz B, 222 Smith T, 312 Uematsu T, 782 Parker LA, 11S Rosman H, 577 Soffer B, 870 Uemura N, 1020 Patzak U, 920 Roth MD, 71S Soffer E, 512 Uenishi K, 1275 Paul C, 1211 Rouilly M, 95 Souhrada M, 881 Ueno K, 1275 Paul G, 175 Roy P, 52, 332 Souppart C, 1147 Ueno K, 342, 806 Paul J, 512 Rushing M, 1027 Spector R, 955 Uhl K, 711 Pechstein B, 995 Spielberg SP, 24 Upmalis DH, 52 Pelland F, 267 Sack M, 1109 Srinivas NR, 670 Urae A, 151 Pentikainen PJ, 43 Sakoda S, 1374 Stevens RE, 52, 290, 332 Penzak SR, 1165 Sakuma A, 151 Stonis L, 157 van Giersbergen P, 283 Perloff MD, 1269 Salek FS, 247 Streetman DS, 376, 1079 Van Osselaer N, 1002 Peters J, 985 Salva P, 1303 Stricker W, 319 Van Peer A, 1002 Petric M, 267 Sanderson SO, 676 Strong A, 547 Vargas R, 1027 Phelps KV, 290, 332 Sandoval E, 145 Studenberg S, 887 Veit M, 731, 920 Phillips G, 198 Sarafian T, 71S Suarez JA, 1187 Velazquez-Armenta EY, 37 Pieniaszek H] Jr, 738, 1326 Sarno M, 774 Sudhop T, 835 Venkataramanan R, 644, 798 Pierre LN, 383 Sato N, 151 Sum Chow MS, 605 Verhaeghe T, 428, 1002, 1341 Pinguier J-L, 1311 Satou M, 81 Sun JX, 198 Verlinden M, 540 Pisegna JR, 512 Sauer J-M, 1219 Sutfin T, 651 Verrill SS, 52 Pittenger AL, 1109 Schindler G, 731, 920 Suzuki A, 1083 Vescio R, 1228 Poindexter JR, 1251 Schlamm H, 395 Svensson CK, 613 Vesell ES, 955 Pollack GM, 569 Schmidli H, 1147 Swan SK, 1109 Victory JM, 461 Vincenti FG, 304 Westervelt P, 412 Wood CC, 881 Yoshida Y, 782 von Bergmann K, 835 Wetzler M, 501 Wurst W, 297 Yoshimura H, 1275 von Moltke LL, 1142 White CM, 963 Yuan C-S, 899 von Moltke LL, 1269 Whitman E, 774 Xu J, 157 Yukawa E, 81 von Nieciecki A, 920 Wilcox DF, 711 Yukawa M, 81 Wilding I, 1200 Yaksh TL, 70 Yurgelun-Todd D, 41S Walden C, 1027 Wilkinson GR, 376, 1079 Yamazaki K, 151 Wallace AW, 437 Wilkinson WE, 388 Yan J-H, 419 Zhang Y, 540 Wallace MS, 70 Wilner KD, 1027 Yanagihara T, 1374 Zhang Z, 870 Wang C, 881 Wilson JT, 24 Yanase K, 151 Zhang Z-F, 103S Wang Y, 1211 Wilton JH, 461 Yanovich S, 395 Zhao Q, 428, 1002, 1341 Ward C, 1147 Winchell GA, 61 Yasui-Furukori N, 100, 1083, 1335 Zhi J, 1011 Warwick MJ, 1116, 1352 Witcher JW, 1219 Yates R, 1237 Zuo Z, 605 Wei GCG, 444 Wittig J, 920 Yates R, 1244 Weidekamm E, 283 Woloski M, 267 Yazaki A, 151 Wells T, 870 Wong PH, 215 Yonezawa E, 342, 806 Subject Index, Volume 42 (2002) ACE inhibitors progressive cholestatic liver disease associated pharmacokinetics and safety of galantamine in comparative effects on dynamic renal potassium with clarithromycin treatment, 676 subjects with hepatic impairment and excretion of ACE inhibition vs angiotensin Age healthy volunteers, 428 receptor blockade in hypertensive patients clinical pharmacokinetics of verteporfin, 547 Amifostine with type II diabetes mellitus, 754 cyclobenzaprine pharmacokinetics, including new dosing regimens for amifostine: a pilot study a double-blind, placebo-controlled, dose-re- effects of age, gender, and hepatic insuffi- to compare the relative bioavailability of oral sponse study of the effectiveness and safety ciency, 61 and subcutaneous administration with intra- of enalapril! for children with hypertension, no effect of age or gender on pharmacokinetics of venous infusion, 166 870 rosuvastatin: a new HMG-CoA reductase in- Aminoglutethimide plasminogen activator inhibitor-1: physiologic hibitor, 1116 role, regulation, and influence of common the influence of hormones and pharmaceutical pharmacologic agents, 1187 Age-related macular degeneration agents on DHEA and DHEA-S concentra- Acetylator phenotype clinical pharmacokinetics of verteporfin, 5 c= N tions: a review of clinical studies, 247 Alcohol Amiodarone acetylator phenotype and genotype in HIV-in- fected patients with and without sulfona- the influence of hormones and pharmaceutical lack of interaction between amiodarone and mide hypersensitivity, 613 agents on DHEA and DHEA-S concentra- mexiletine in cardiac arrhythmia patients, Acute myeloid leukemia tions: a review of clinical studies, 247 342 pharmacodynamic modeling of thrombopoietin, Alfentanil Amitriptyline platelet, and megakaryocyte dynamics in pa- concentration-effect relationships for intrave- the influence of hormones and pharmaceutical tients with acute myeloid leukemia undergo- nous alfentanil and ketamine infusions in agents on DHEA and DHEA-S concentra- ing dose intensive chemotherapy, 501 human volunteers: effects on acute thresh- tions: a review of clinical studies, 247 olds and capsaicin-evoked hyperpathia, 70 Acute myocardial infarction (AMI) pharmacokinetic evaluation of possible interac- Alfuzosin plasminogen activator inhibitor-1: physiologic tion between selected concomitant medica- role, regulation, and influence of common pharmacokinetics and safety of a single oral dose tions and orlistat at steady state in healthy pharmacologic agents, 1187 of once-daily alfuzosin, 10 mg, in male sub- subjects, 1011 jects with mild to severe renal impairment, Adolescents Ampicillin 1311 adolescents prenatally exposed to marijuana: ex- Allergic rhinitis the influence of hormones and pharmaceutical amination of facets of complex behaviors and agents on DHEA and DHEA-S concentra- comparisons with the influence of in utero a double-blind, placebo-controlled study of effi- tions: a review of clinical studies, 247 cigarettes, 97S cacy and safety of ebastine 20 mg once daily given with and without food in treatment of Amprenavir Adrenal androgoe ns seasonal allergic rhinitis, 1097 pharmacokinetics of GW433908, a prodrug of the influence of hormones and pharmaceutical a new solution-based intranasal triamcinolone amprenavir, in healthy male volunteers, 887 atigoennst:s a orne viDewH EAof clainndi calD HsEtuAd-iSes , c2o4n7c entra- arceentnioanli de alfloerrgmiucl atirohinn itiins : pathioewnt s dwoietsh tphee- Analgesic agents Adrenergic blocking agents pharmacokinetic/pharmacodynamic profile comparison of the pharmacokinetics of the aignefnltuse ncoen ofD HhEoAr monaends DanHdE A-phSa rmcaocnecuetnitcraal- afoqru ecoourst isoslu spseunpspiroens-sbiaosne d cofmorpmaurlea tiowni,t h 66a2n ofoxrymcuoldaotnioen s,a dm1i9n2 istered in three Percocet tions: a review of clinical studies, 247 Almotriptan concentration-effect relationships for intrave- nous alfentanil and ketamine infusions in a-1-Adrenoreceptor antagonists absolute bioavailability, pharmacokinetics, and human volunteers: effects on acute thresh- urinary excretion of the novel antimigraine single- and multiple-dose pharmacokinetics of olds and capsaicin-evoked hyperpathia, 70 agent almotriptan in healthy male volun- fiduxosin under nonfasting conditions in healthy male subjects, 540 teers, 1303 contribution of morphine-6-glucuronide to Alpha-tocopherol antinociception following intravenous ad- Adrenocorticotropin ministration of morphine to healthy volun- the influence of hormones and pharmaceutical the influence of hormones and pharmaceutical teers, 569 agents on DHEA and DHEA-S concentra- agents on DHEA and DHEA-S concentra- tions: a review of clinical studies, 247 a controlled comparative study of ibuprofen tions: a review of clinical studies, 247 arginate vs conventional ibuprofen in treat- Alprazolam Adverse events ment of postoperative dental pain, 904 the influence of hormones and pharmaceutical bleeding associated with eptifibatide targeting agents on DHEA and DHEA-S concentra- efficacy and tolerability of nonprescription higher risk patients with acute coronary syn- ibuprofen vs celecoxib for dental pain, 912 tions: a review of clinical studies, 247 dromes: incidence and multivariate risk fac- tors, 1366 Alzheimer’s disease miniomxaylc odionntee,ra ct9i2o8n between gatifloxacin and hypotension and bradycardia in a healthy volun- electrocardiographic effects of rivastigmine, 558 teer following a single 5 mg dose of galantamine pharmacokinetics, safety, and transcutaneous electrical acupoint stimulation olanzapine, 104 tolerability profiles are similar in healthy potentiates analgesic effect of morphine, 899 microsomal enzyme induction and clinical ag- caucasian and Japanese subjects, 1002 Angiotensin receptor blockers (ARB) gravation of porphyria: the evaluation of hu- pharmacokinetic and safety assessments of comparative effects on dynamic renal potassium man urinary 6B-hydroxycortisol/cortisol ra- galantamine and risperidone after the two excretion of ACE inhibition vs angiotensin tio as the index of hepatic CYP3A4 activity, drugs are administered alone and together, receptor blockade in hypertensive patients 1374 1341 with type II diabetes mellitus, 754 Animals Antidepressants Antilipemic agents endocrine disruptors: A new scientific role for effect of terbinafine on pharmacokinetics and the influence of hormones and pharmaceutical clinical pharmacologists? impact on human pharmacodynamics of desipramine in agents on DHEA and DHEA-S concentra- health, wildlife, and the environment, 7 healthy volunteers identified as cytochrome tions: a review of clinical studies, 247 Antiarrhythmic drugs P450 2D6 (CYP2D6) extensive metabolizers, Antimalarial drugs effects of azimilide on heart rate and ECG con- 1211 interaction trial between artemether-lumefantrine duction intervals during sinus rhythm in pa- the influence of hormones and pharmaceutical (Riamet’) and quinine in healthy subjects, tients with a history of atrial fibrillation, 388 agents on DHEA and DHEA-S concentra- 1147 lack of interaction between amiodarone and tions: a review of clinical studies, 247 Antimicrobial drugs mexiletine in cardiac arrhythmia patients, Antidiabetic agents clinical pharmacology of antimicrobial use in hu- 342 insulin-metformin combination therapy in obese mans and animals, 587 Anti-arthritis drugs patients with type 2 diabetes, 89 Antinociception celecoxib does not affect the antiplatelet activity lack of effect of sucralfate on absorption and of aspirin in healthy volunteers, 1027 pharmacokinetics of rosiglitazone, 670 contribution of morphine-6-glucuronide to antinociception following intravenous ad- effect of rofecoxib on the pharmacokinetics of no effect of the novel antidiabetic agent ministration of morphine to healthy volun- chronically administered oral contraceptives nateglinide on pharmacokinetics and antico- teers, 569 in healthy female volunteers, 215 agulant properties of warfarin in healthy vol- Antiparasitic drugs effects of celecoxib and diclofenac on blood pres- unteers, 1358 sure, renal function, and vasoactive safety, tolerability, and pharmacokinetics of esca- prostanoids in young and elderly subjects, pharmacokinetics and pharmacodynamics of ex- lating high doses of ivermectin in healthy 985 twietnhd edi-mrmeeldeiaastee -reglleiapiszei dgel ipGiIzTidSe icno mpaptaireentds adult subjects, 1122 effects of meloxicam on platelet function in with type II diabetes mellitus, 651 Antipsychotic agents healthy adults: a randomized, double-blind, pioglitazone: effect on CYP3A4 activity, 1299 hypotension and bradycardia in a healthy volun- placebo-controlled trial, 881 teer following a single 5 mg dose of efficacy and tolerability of nonprescription Antiepileptic drugs olanzapine, 104 ibuprofen vs celecoxib for dental pain, 912 clinical pharmacology: drugs as a benefit and/or lack of correlation between steady-state plasma Antibiotics risk in sudden unexpected death in epi- concentrations of haloperidol and clinical pharmacology of antimicrobial use in hu- lepsy?, 123 risperidone, 1083 mans and animals, 587 multiple-dose, linear, dose-proportional Antiretroviral drugs pharmacokinetics of retigabine in healthy comparative target site pharmacokinetics of im- effect of food on the pharmacokinetics of (-) and volunteers, 175 mediate- and modified-release formulations (+) dOTC when administered as an oral of cefaclor in humans, 403 pharmacoepidemiologic investigation of racemate, 658 clonazepam relative clearance by mixed-ef- the effect of erythromycin and clarithromycin on pharmacokinetics of GW433908, a prodrug of fect modeling using routine clinical pharmacokinetics of intravenous digoxin in amprenavir, in healthy male volunteers, 887 healthy volunteers, 1159 8p1h armacokinetic data in Japanese patients, Antithrombotic agents impairment of ciprofloxacin absorption by cal- cium polycarbophil, 806 Antifungal agents safety, pharmacokinetics, and time course of pharmacologic response of the active metab- the influence of hormones and pharmaceutical effect of terbinafine on pharmacokinetics and olite of roxifiban, XV459, a glycoprotein IIb/ agents on DHEA and DHEA-S concentra- pharmacodynamics of desipramine in Illa antagonist, following oral administration tions: a review of clinical studies, 247 healthy volunteers identified as cytochrome in healthy volunteers, 738 lack of bioequivalence of ciprofloxacin when ad- P450 2D6 (CYP2D6) extensive metabolizers, Antituberculosis chemotherapy ministered with calcium-fortified orange 1211 juice: a new twist on an old interaction, 461 safety and pharmacokinetics of oral voriconazole a simplified method for detecting isoniazid com- in patients at risk of fungal infection: a dose pliance in patients receiving antituberculosis minimal interaction between gatifloxacin and escalation study, 395 chemotherapy, 151 oxycodone, 928 pharmacokinetics of cefoperazone and Antihistamines Anxiolytic agents effect of fluconazole on the pharmacokinetics sulbactam in liver transplant patients, 644 a double-blind, placebo-controlled study of effi- progressive cholestatic liver disease associated cacy and safety of ebastine 20 mg once daily abnrdo mapzheapramma:c odayn naampipclsic atoifo no raol f aenlde ctrreocetna-l with clarithromycin treatment, 676 gsievaesnon awli tha llaenrgdi c wirthhinoiutti s, fo1o0d9 7i n treatment of cephalography as the pharmacodynamic a study of the interaction potential of method, 183 azithromycin and clarithromycin with fexofenadine transport in Caco-2 cells: inhibition Arbutin atorvastatin in healthy volunteers, 444 with verapamil and ritonavir, 1269 urinary excretion and metabolism of arbutin after Anticoagulation Antihypertensive drugs oral administration of Arctostaphylos uvae effect of modafinil at steady state on the single- comparative effects on dynamic renal potassium ursi extract as film-coated tables and aqueous dose pharmacokinetic profile of warfarin in excretion of ACE inhibition vs angiotensin solution in healthy humans, 920 healthy volunteers, 205 receptor blockade in hypertensive patients Artemether-lumefantrine increased sensitivity to warfarin in elderly His- with type II diabetes mellitus, 754 interaction trial between artemether-lumefantrine panics, 145 a double-blind, placebo-controlled, dose-re- (Riamet’) and quinine in healthy subjects, no effect of the novel antidiabetic agent sponse study of the effeciiveness and safety 1147 nateglinide on pharmacokinetics and antico- of enalapril for children with hypertension, agulant properties of warfarin in healthy vol- 870 Arterial elasticity unteers, 1358 effect of doxazosin on arterial elasticity: func- effect of doxazosin on arterial elasticity: func- Anticonvulsants tional vs structural changes, 1105 tional vs structural changes, 1105 the influence of hormones and pharmaceutical plasminogen activator inhibitor-1: physiologic Aspirin agents on DHEA and DHEA-S concentra- role, regulation, and influence of common celecoxib does not affect the antiplatelet activity tions: a review of clinical studies, 247 pharmacologic agents, 1187 of aspirin in healthy volunteers, 1027 Asthma Benzodiazepines drugs are administered alone and together. bioavailability and metabolism of mometasone effect of dietary fat content in meals on 1341 furoate: pharmacology vs methodology, 383 pharmacokinetics of quazepam, 1335 sequential first-pass metabolism of nortilidine: a comparison of methods for assessing hypotha- effect of fluconazole on the pharmacokinetic: the active metabolite of the synthetic opioid lamic-pituitary-adrenal (HPA) axis activity in and pharmacodynamics of oral and rectal drug tilidine, 1257 asthma patients treated with inhaled bromazepam: an application of electroen- systemic availability and pharmacokinetics of corticosteroids, 319 cephalography as the pharmacodynamic thymol in humans, 731 the new phosphodiesterase 4 inhibitor method, 183 Bioequivalence roflumilast is efficacious in exercise-induced the influence of hormones and pharmaceutical bioequivalence of two formulations of didanosine, asthma and leads to suppression of LPS-stim- agents on DHEA and DHEA-S concentra- encapsulated enteric-coated beads and buf- ulated TNF-a ex vivo, 297 tions: a review of clinical studies, 247 fered tablet, in healthy volunteers and HIV- Atherosclerosis limited sampling strategy to predict AUC of the infected subjects, 791 clinical manifestation of atherosclerotic periph- CadYuPlt3sA: apphpelnicoattyipoinn g to prvoabreio usm idaaszsoayl amt echi-n bioeqtueistvianlaeln ce prtoedsuticntgs : forw hlaotca llyr olaec tinfogr gagsatrmomina- terraela tamretnetri alo f diinsteearsmei ttaenndt rcollae udoifc actiiloosnt,a zo1l2 91i n niques, 376 scintigraphy?, 1200 Beta-adrenoreceptor antagonists an evaluation of bioequivalence of two 7-day Atomoxetine pharmacokinetic and pharmacodynamic differ- 178-estradiol transdermal delivery systems effect of potent CYP2D6 inhibition by paroxetine ences between ocular and nasal installation by anatomical site, 1134 on atomoxetine pharmacokinetics, 1219 of carteolol on intraocular pressure and heart lack of bioequivalence of ciprofloxacin when ad- Atorvastatin triavtiet y,i n 1J0a2p0a nese men with high CYP2D6 ac- ministered with calcium-fortified orange pharmacokinetic and pharmacodynamic assess- juice: a new twist on an old interaction, 461 ments of HMG-CoA reductase inhibitors Beta-lactam antibiotics Biotransformation when coadministered with everolimus, 222 comparative target site pharmacokinetics of im- concordance between tramadol and pharmacokinetic evaluation of possible interac- mediate- and modified-release formulations dextromethorphan parent/metabolite ratios: tion between selected concomitant medica- of cefaclor in humans, 403 the influence of CYP2D6 and non-CYP2D6 tions and orlistat at steady state in healthy Beta-lactamase inhibitor pathways on biotransformation, 24 subjects, 1011 pharmacokinetics of cefoperazone and Bisphosphonates a study of the interaction potential of sulbactam in liver transplant patients, 644 pharmacokinetics and pharmacodynamics of azithromycin and clarithromycin with Bioavailability zoledronic acid in cancer patients with bone atorvastatin in healthy volunteers, 444 absolute bioavailability, pharmacokinetics, and metastases, 1228 Attention-deficit hyperactivity disorder (ADHD) urinary excretion of the novel antimigraine Bleeding effect of potent CYP2D6 inhibition by paroxetine agent almotriptan in healthy male volun- bleeding associated with eptifibatide targeting on atomoxetine pharmacokinetics, 1219 teers, 1303 higher risk patients with acute coronary syn- pemoline ingestion in children: a report of five bioavailability and metabolism of mometasone dromes: incidence and multivariate risk fac- cases and review of the literature, 275 furoate: pharmacology vs methodology, 383 tors, 1366 Autonomic drugs bioavailability study of a1 200 mg miconazole ni- Blood pressure trate vaginal ovule in healthy female adults, the influence of hormones and pharmaceutical 52 effects of celecoxib and diclofenac on blood pres- agents on DHEA and DHEA-S concentra- sure, renal function, and vasoactive tions: a review of clinical studies, 247 comparative pharmacokinetics of lovastatin ex- prostanoids in young and elderly subjects, tended-release tablets and lovastatin imme- 985 Azimilide diate-release tablets in humans, 198 Bone metastases effects of azimilide on heart rate and ECG con- cyclobenzaprine pharmacokinetics, including duction intervals during sinus rhythm in pa- effects of age, gender, and hepatic insuffi- pharmacokinetics and pharmacodynamics of tients with a histoofr atryia l fibrillation, 388 ciency, 61 zoledronic acid in cancer patients with bone metastases, 1228 Azithromycin effect of estrogen treatment and vitamin D status on differing bioavailabilities of calcium car- Bone turnover a study of the interaction potential of azithromycin and clarithromycin with bonate and calcium citrate, 1251 short-term effects of new synthetic conjugated atorvastatin in healthy volunteers, 444 effect of food on the oral bioavailability of estrogens on biochemical markers of bone didanosine from encapsulated enteric- turnover, 290 Bearberry coated beads, 419 Bosentan urinary excretion and metabolism of arbutin after effect of phosphate binders on supplemental iron influence of food intake and formulation on the oral administration of Arctostaphylos uvae absorption in healthy subjects, 1171 pharmacokinetics and metabolism of suorlsuit eixotnr acitn ahse aflitlhmy- cohautmeadn st,a bl9es2 0 and aqueous influence of food intake and formulation on the bosentan, a dual endothelin receptor antago- pharmacokinetics and metabolism of nist, 283 Benfluorex bosentan, a dual endothelin receptor antago- Botanicals. See Herbal medicine the influence of hormones and pharmaceutical nist, 283 Breast cancer agents on DHEA and DHEA-S concentra- a mechanistic approach to understanding factors multiple-dose, safety, pharmacokinetics, and tions: a review of clinical studies, 247 affecting drug absorption, 620 pharmacodynamics of a new selective estro- Benign prostatic hypertrophy (BPH) minimal interaction between gatifloxacin and gen receptor modulator, ERA-923, in healthy pharmacokinetics and safety of as ingle oral dose oxycodone, 928 postmenopausal women, 157 of once-daily alfuzosin, 10 mg, in male sub- new dosing regimens for amifostine: a pilot study Bromazepam jects with mild to severe renal impairment, to compare the relative bioavailability of oral effect of fluconazole on the pharmacokinetics 1311 and subcutaneous administration with intra- and pharmacodynamics of oral and rectal single- and multiple-dose pharmacokinetics of venous infusion, 166 bromazepam: an application of electroen- fiduxosin under nonfasting conditions in pharmacokinetic and safety assessments of cephalography as the pharmacodynamic healthy male subjects, 540 galantamine and risperidone after the two method, 183 Bromocriptine Cannabinoids Center for Drug Evaluation and Research the influence of hormones and pharmaceutical effects of smoked marijuana in healthy and HIV+ (CDER) agents on DHEA and DHEA-S concentra- marijuana smokers, 34S advanced science education in the regulatory tions: a review of clinical studies, 247 Cannabis. See Marijuana arena: The Center for Drug Evaluation and Caco-2 cells Capsaicin Research experience at the FDA, 711 fexofenadine transport in Caco-2 cells: inhibition concentration-effect relationships for intrave- Central nervous system drugs with verapamil and ritonavir, 1269 nous alfentanil and ketamine infusions in the influence of hormones and pharmaceutical Calcineurin inhibitors human volunteers: effects on acute thresh- agents on DHEA and DHEA-S concentra- effect of calcineurin inhibitor therapy on P-gp ex- olds and capsaicin-evoked hyperpathia, 70 tions: a review of clinical studies, 247 pression and function in lymphocytes of re- Carbamazepine Cephalosporins nal transplant patients, 304 carbamazepine decreases antihypertensive effect pharmacokinetics of cefoperazone and Calcium carbonate of nilvadipine, 100 sulbactam in liver transplant patients, 644 effect of estrogen treatment and vitamin D status the influence of hormones and pharmaceutical Cetrorelix acetate on differing bioavailabilities of calcium car- agents on DHEA and DHEA-S concentra- bonate and calcium citrate, 1251 tions: a review of clinical studies, 247 novel formulations of cetrorelix acetate in Calcium channel blockers Carboplatin healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics, 995 the influence of hormones and pharmaceutical toxicity of high-dose carboplatin: ultrafiltered agents on DHEA and DHEA-S concentra- and not total plasma pharmacokinetics is of Chickenpox tions: a review of clinical studies, 247 clinical relevance, 762 serum concentrations, efficacy, and safety of a Calcium citrate Cardiovascular disease new, intravenously administered varicella effect of estrogen treatment and vitamin D status bleeding associated with eptifibatide targeting zoster immune globulin in pregnant women, on differing bioavailabilities of calcium car- higher risk patients with acute coronary syn- 267 bonate and calcium citrate, 1251 dromes: incidence and multivariate risk fac- Children. See Pediatrics Calcium polycarbophil tors, 1366 Chinese traditional medicine plasminogen activator inhibitor-1: physiologic impairment of ciprofloxacin absorption by cal- Coriolus versicolor: a medicinal mushroom with role, regulation, and influence of common cium polycarbophil, 806 promising immunotherapeutic values, 976 pharmacologic agents, 1187 impairment of mycophenolate mofetil absorp- Cardiovascular drugs hawthorn, 605 tion by calcium polycarbophil, 1275 the influence of hormones and pharmaceutical Schizonepeta tenuifolia: chemistry, pharmacol- Calcium sensitizers agents on DHEA and DHEA-S concentra- ogy, and clinical applications, 30 pharmacodynamics and safety of a new calcium tioo ns: a review of clinical studies, 247 Cholinesterase inhibitors sdeunrsiintgiz earn, elxetveonsdiemde ndinafnu,s ioann d ini tsp amteiteantbso liwtietsh Carteolol electrocardiographic effects of rivastigmine, 558 severe heart failure, 43 pharmacokinetic and pharmacodynamic differ- galantamine pharmacokinetics, safety, and ences between ocular and nasal installation Cancer of carteolol on intraocular pressure and heart tolerability profiles are similar in healthy marijuana smoking and head and neck cancer, rate in Japanese men with high CYP2D6 ac- caucasian and Japanese subjects, 1002 1038S tivity, 1020 pharmacokinetic and safety assessments of galantamine and risperidone after the two Cancer chemotherapy Cefaclor drugs are administered alone and together, Coriolus versicolor: a medicinal mushroom with comparative target site pharmacokinetics of im- 1341 promising immunotherapeutic values, 976 mediate- and modified-release formulations pharmacodynamic modeling of thrombopoietin, of cefaclor in humans, 403 pharsmuabcjoekcitnse tiwcist h anhde psaatfiect y iofm pgaailramnteanmti nea nidn platelet, and megakaryocyte dynamics in pa- Cefodizime healthy volunteers, 428 tients with acute myeloid leukemia undergo- the influence of hormones and pharmaceutical ing dose intensive chemotherapy, 501 agents on DHEA and DHEA-S concentra- Choroidal neovascularization pharmacokinetic study of infusional valspodar, tions: a review of clinical studies, 247 clinical pharmacokinetics of verteporfin, 547 412 Cefoperazone Chronic obstructive pulmonary disease (COPD) toxicity of high-dose carboplatin: ultrafiltered pharmacokinetics of cefoperazone and the new phosphodiesterase 4 inhibitor and not total plasma pharmacokinetics is of sulbactam in liver transplant patients, 644 roflumilast is efficacious in exercise-induced clinical relevance, 762 Celecoxib asthma and leads to suppression of LPS-stim- Cancer patients celecoxib does not affect the antiplatelet activity ulated TNF-o ex vivo, 297 pharmacokinetics and pharmacodynamics of of aspirin in healthy volunteers, 1027 Chronotherapy zoledronic acid in cancer patients with bone effects of celecoxib and diclofenac on blood pres- pharmacokinetics of diethylcarbamazine after metastases, 1228 sure, renal function, and vasoactive single oral dose at two different times of day pharmacokinetics of histamine dihydrochloride prostanoids in young and elderly subjects, in human subjects, 327 in healthy volunteers and cancer patients: 985 implications for combined immunotherapy Cilostazol with interleukin-2, 774 efficiabcuyp roafnedn vtso lceerlaebciolxiitby foofr dneontnaplr espacirni,p t9i1o2 n clinical manifestation of atherosclerotic periph- Candesartan eral arterial disease and role of cilostazol in Cenestin treatment of intermittent claudication, 1291 comparative effects on dynamic renal potassium evaluation of single- and multiple-dose excretion of ACE inhibition vs angiotensin pharmacokinetics of synthetic conjugated Ciprofloxacin receptor blockade in hypertensive patients estrogens (Cenestin’ tablets): a slow-release impairment of ciprofloxacin absorption by cal- with type II diabetes mellitus, 754 estrogen replacement product, 332 cium polycarbophil, 806 Cannabidiol short-term effects of new synthetic conjugated lack of bioequivalence of ciprofloxacin when ad- cannabidiol: an overview of some pharmacologi- estrogens on biochemical markers of bone ministered with calcium-fortified orange cal aspects, 11S turnover, 290 juice: a new twist on an old interaction, 461 1387 Clarithromycin Co-artemether tions and orlistat at steady state in healthy the effect of erythromycin and clarithromycin on interaction trial between artemether-lumefantrine subjects, 1011 pharmacokinetics of intravenous digoxin in (Riamet’) and quinine in healthy subjects, CYP3A4 healthy volunteers, 1159 1147 limited sampling strategy to predict AUC of the progressive cholestatic liver disease associated Compliance CYP3A phenotyping probe midazolam in with clarithromycin treatment, 676 a simplified method for detecting isoniazid com- adults: application to various assay tech- a study of the interaction potential of pliance in patients receiving antituberculosis niques, 376 azithromycin and clarithromycin with chemotherapy, 151 microsomal enzyme induction and clinical ag- atorvastatin in healthy volunteers, 444 Congestive heart failure gravation of porphyria: the evaluation of hu- Clearance. See Drug clearance the effects of concomitant administration of man urinary 6$-hydroxycortisol/cortisol ra- theophylline and _ toborinone’ on tio as the index of hepatic CYP3A4 activity, Clinical practice guidelines pharmacokinetics of both compounds in 1374 valuing knowledge and the knowledge of values: poor and extensive metabolizers via pioglitazone: effect on CYP3A4 activity, 1299 uscnrdiebrinsgt,a n4d7i5n g guideline-incongruent pre- CYP2D6, 492 Cystitis pharmacokinetics of toborinone in subjects with Clinical studies congestive heart failure and concomitant re- urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae clinical pharmacology: drugs as a benefit and/or nal impairment and/or concomitant hepatic ursi extract as film-coated tables and aqueous risk in sudden unexpected death in epi- impairment, 1318 solution in healthy humans, 920 lepsy?, 123 Conjugated estrogens Cytochrome P450 a double-blind, placebo-controlled study of effi- evaluation of single- and multiple-dose pharma- cacy and safety of ebastine 20 mg once daily cokinetics of synthetic conjugated estrogens concordance between tramadol and given with and without food in treatment of (Cenestin® tablets): a slow-release estrogen re- dextromethorphan parent/metabolite ratios: seasonal allergic rhinitis, 1097 placement product, 332 the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation, 24 effect of doxazosin on arterial elasticity: func- short-term effects of new synthetic conjugated tional vs structural changes, 1105 estrogens on biochemical markers of bone effect of potent CYP2D6 inhibition by paroxetine evaluation of renal function in transplant pa- turnover, 290 on atomoxetine pharmacokinetics, 1219 tients on tacrolimus therapy, 798 Corticosteroids effect of terbinafine on pharmacokinetics and the influence of hormones and pharmaceutical bioavailability and metabolism of mometasone pharmacodynamics of desipramine in agents on DHEA and DHEA-S concentra- furoate: pharmacology vs methodology, 383 healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers, tions: a review of clinical studies, 247 a comparison of methods for assessing hypotha- 1211 insulin-metformin combination therapy in obese lamic-pituitary-adrenal (HPA) axis activity in patients with type 2 diabetes, 89 asthma patients treated with inhaled Cytokine monotherapy corticosteroids, 319 pharmacokinetics of histamine dihydrochloride an introduction to clinical research and drug de- velopment for pharmacy and pharmacology Corticotropin-releasing hormone in healthy volunteers and cancer patients: graduate students, 867 the influence of hormones and pharmaceutical implications for combined immunotherapy agents on DHEA and DHEA-S concentra- with interleukin-2, 774 serum concentrations, efficacy, and safety of a new, intravenously administered varicella tions: a review of clinical studies, 247 Cytoprotective drugs zoster immune globulin in pregnant women, COX-2 inhibitors new dosing regimens for amifostine: a pilot study 267 celecoxib does not affect the antiplatelet activity to compare the relative bioavailability of oral which studies of therapy merit credence? vita- of aspirin in healthy volunteers, 1027 and subcutaneous administration with intra- min E and estrogen therapy as cautionary ex- effect of rofecoxib on the pharmacokinetics of venous infusion, 166 amples, 955 chronically administered oral contraceptives Danazol which studies of therapy merit credence? vita- in healthy female volunteers, 215 the influence of hormones and pharmaceutical min E and estrogen therapy as cautionary ex- effects of celecoxib and diclofenac on blood pres- agents on DHEA and DHEA-S concentra- amples, 955 sure, renal function, and vasoactive tions: a review of clinical studies, 247 Clinical trials prostanoids in young and elderly subjects, Dehydroepiandrosterone (DHEA) 985 HIV testing in early clinical trials: who should the influence of hormones and pharmaceutical effects of meloxicam on platelet function in decide whether it is warranted?, 601 agents on DHEA and DHEA-S concentra- healthy adults: a randomized, double-blind, the recruitment of normal healthy volunteers: a placebo-controlled trial, 881 tions: a review of clinical studies, 247 review of the literature on use of financial in- Dental pain efficacy and tolerability of nonprescription centives, 365 ibuprofen vs celecoxib for dental pain, 912 a controlled comparative study of ibuprofen Clomiphene Cyclobenzaprine arginate vs conventional ibuprofen in treat- the influence of hormones and pharmaceutical cyclobenzaprine pharmacokinetics, including ment of postoperative dental pain, 904 agents on DHEA and DHEA-S concentra- effects of age, gender, and hepatic insuffi- efficacy and tolerability of nonprescription tions: a review of clinical studies, 247 ciency, 61 ibuprofen vs celecoxib for dental pain, 912 Clomipramine Cyclosporine Desipramine the influence of hormones and pharmaceutical differential influence of two cyclosporine formu- effect of terbinafine on pharmacokinetics and agents on DHEA and DHEA-S concentra- lations on everolimus pharmacokinetics: a pharmacodynamics of desipramine in tions: a review ofc linical studies, 247 clinically relevant pharmacokinetic interac- healthy volunteers identified as cytochrome Clonazepam tion, 95 P450 2D6 (CYP2D6) extensive metabolizers, pharmacoepidemiologic investigation of effect of calcineurin inhibitor therapy on P-gp ex- 1211 clonazepam relative clearance by mixed-ef- pression and function in lymphocytes of re- Dexamethasone fect modeling using routine clinical nal transplant patients, 304 the influence of hormones and pharmaceutical pharmacokinetic data in Japanese patients, pharmacokinetic evaluation of possible interac- agents on DHEA and DHEA-S concentra- 81 tion between selected concomitant medica- tions: a review of clinical studies, 247 Dextroamphetamine Doxazosin effect of phosphate binders on supplemental iron steady-state pharmacokinetics and tolerability of effect of doxazosin on arterial elasticity: func- absorption in healthy subjects, 1171 modafinil administered alone or in combina- tional vs structural changes, 1105 effect of potent CYP2D6 inhibition by paroxetine tion with dextroamphetamine in healthy vol- Drug absorption on atomoxetine pharmacokinetics, 1219 unteers, 450 impairment of ciprofloxacin absorption by cal- effect of rofecoxib on the pharmacokinetics of Dextromethorphan cium polycarbophil, 806 chronically administered oral contraceptives in healthy female volunteers, 215 concordance between tramadol and lack of effect of sucralfate on absorption and dextromethorphan parent/metabolite ratios: pharmacokinetics of rosiglitazone, 670 effect of seville orange juice and grapefruit juice the influence of CYP2D6 and non-CYP2D6 on indinavir pharmacokinetics, 1165 a mechanistic approach to understanding factors pathways on biotransformation, 24 affecting drug absorption, 620 effect of terbinafine on pharmacokinetics and Diabetes mellitus pharmacodynamics of desipramine in Drug abuse. See Marijuana healthy volunteers identified as cytochrome comparative effects on dynamic renal potassium excretion of ACE inhibition vs angiotensin Drug binding P450 2D6 (CYP2D6) extensive metabolizers, receptor blockade in hypertensive patients evaluation of highly bound drugs: interspecies, 1211 with type II diabetes mellitus, 754 intersubject, and related comparisons, 971 the effects of concomitant administration of insulin-metformin combination therapy in obese Drug clearance theophylline and toborinone’ on pharmacokinetics of both compounds in patients with type 2 diabetes, 89 pharmacoepidemiologic investigation of poor and extensive metabolizers via lack of effect of sucralfate on absorption and clonazepam relative clearance by mixed-ef- CYP2D6, 492 pharmacokinetics of rosiglitazone, 670 fect modeling using routine clinical pharmacokinetic data in Japanese patients, fexofenadine transport in Caco-2 cells: inhibition no effect of the novel antidiabetic agent with verapamil and ritonavir, 1269 61 nateglinide on pharmacokinetics and antico- agulant properties of warfarin in healthy vol- single plasma concentrations of 1’- impaciirumme ntp olyofc arcbiporpohfillo,x a8c0i6n absorption by cal- unteers, 1358 hydroxymidazolam or the ratio of 1’- hydroxymidazolam:midazolam do not pre- impairment of mycophenolate mofetil absorp- pharmacokinetics and pharmacodynamics of ex- dict midazolam clearance in healthy sub- tion by calcium polycarbophil, 1275 tended-release glipizide GITS compared jects, 1079 with immediate-release glipizide in patients the influence of hormones and pharmaceutical with type II diabetes mellitus, 651 Drug dependency agents on DHEA and DHEA-S concentra- development and consequences of cannabis de- tions: a review of clinical studies, 247 pioglitazone: effect on CYP3A4 activity, 1299 pendence, 28S interaction trial between artemether-lumefantrine Diclofenac effects of smoked marijuana in healthy and HIV+ (Riamet’) and quinine in healthy subjects, effects of celecoxiabnd diclofenac on blood pres- marijuana smokers, 34S 1147 sure, renal function, and vasoactive prostanoids in young and elderly subjects, marimjoudaenla, w2i0tSh drawal syndrome in the animal is it trieoanlsl y wOitKh tao nteakwe tthwiiss t,w i4t3h7 food? old interac- 985 Didanosine Drug development lack moifn biisoteeqrueidv alweintche coaf lcciipurmo-ffloorxtaicfiine d wheonra nagde- bioequivalence of two formulations of bioequivalence testing for locally acting gastroin- juice: a new twist on an old interaction, 461 testinal products: what role for gamma didanosine, encapsulated enteric-coated scintigraphy?, 1200 lack of effect of sucralfate on absorption and beads and buffered tablet, in healthy volun- pharmacokinetics of rosiglitazone, 670 teers and HIV-infected subjects, 791 evaluation of highly bound drugs: interspecies, intersubject, and related comparisons, 971 lack of interaction between amiodarone and effect of food on the oral bioavailability of mexiletine in cardiac arrhythmia patients, didanosine from encapsulated enteric- HIV testing in early clinical trials: who should 342 coated beads, 419 decide whether it is warranted?, 601 minimal interaction between gatifloxacin and Dietary fat absorption an introduction to clinical research and drug de- oxycodone, 928 velopment for pharmacy and pharmacology pharmacokinetic evaluation of possible interac- graduate students, 867 no effect of rosuvastatin on pharmacokinetics of tion between selected concomitant medica- digoxin in healthy volunteers, 1352 tions and orlistat at steady state in healthy the recruitment of normal healthy volunteers: a subjects, 1011 review of the literature on use of financial in- pharmacokinetic and pharmacodynamic assess- centives, 365 ments of HMG-CoA reductase inhibitors Diethylcarbamazine when coadministered with everolimus, 222 Drug interactions pharmacokinetics of diethylcarbamazine after pharmacokinetic and safety assessments of single oral dose at two different times of day carbamazepine decreases antihypertensive effect galantamine and risperidone after the two in human subjects, 327 of nilvadipine, 100 drugs are administered alone and together, Digoxin celecoxib does not affect the antiplatelet activity 1341 of aspirin in healthy volunteers, 1027 the effect of erythromycin and clarithromycin on pharmacokinetic evaluation of possible interac- pharmacokinetics of intravenous digoxin in differential influence of two cyclosporine formu- tion between selected concomitant medica- healthy volunteers, 1159 lations on everolimus pharmacokinetics: a tions and orlistat at steady state in healthy clinically relevant pharmacokinetic interac- subjects, 1011 no edffiegcot xionf rions uhveaaslttahtyi n voolnu ntpehearrsm, ac1o3k5i2n etics of tion, 95 plasminogen activator inhibitor-1: physiologic the effect of erythromycin and clarithromycin on role, regulation, and influence of common Dopamine pharmacokinetics of intravenous digoxin in pharmacologic agents, 1187 the influence of hormones and pharmaceutical healthy volunteers, 1159 steady-state pharmacokinetics and tolerability of agents on DHEA and DHEA-S concentra- effect of estrogen treatment and vitamin D status modafinil administered alone or in combina- tions: a review of clinical studies, 247 on differing bioavailabilities of calcium car- tion with dextroamphetamine in healthy vol- dOTC bonate and calcium citrate, 1251 unteers, 450 effect of food on the pharmacokinetics of (-) and effect of modafinil at steady state on the single- a study of the interaction potential of (+) dOTC when administered as an oral dose pharmacokinetic profile of warfarin in azithromycin and clarithromycin with racemate, 658 healthy volunteers, 205 atorvastatin in healthy volunteers, 444 Drug metabolism increased sensitivity to warfarin in elderly Erythromycin absolute bioavailability, pharmacokinetics, and panics, 145 the effect of erythromycin and clarithromycin on urinary excretion of the novel antimigraine Electrocardiogram pharmacokinetics of intravenous digoxin in agent almotriptan in healthy male volun- healthy volunteers, 1159 effects of azimilide on heart rate and ECG con- teers, 1303 duction intervals during sinus rhythm in pa- Estradiol bioavailability and metabolism of mometasone tients with a history of atrial fibrillation, 388 an evaluation of bioequivalence of two 7-day furoate: pharmacology vs methodology, 383 electrocardiographic effects of rivastigmine, 558 17B-estradiol transdermal delivery systems concordance between tramadol and by anatomical site, 1134 dextromethorphan parent/metabolite ratios: Electroencephalography oral hormone replacement therapy: factors that the influence of CYP2D6 and non-CYP2D6 effect of fluconazole on the pharmacokinetics influence the estradiol concentrations pathways on biotransformation, 24 and pharmacodynamics of oral and rectal achieved in a multiracial study population, effect of potent CYP2D6 inhibition by paroxetine bremazepam: an application of electroen- on atomoxetine pharmacokinetics, 1219 cephalography as the pharmacodynamic 137 method, 183 Estrogens effect of seville orange juice and grapefruit juice on indinavir pharmacokinetics, 1165 Elephantiasis effect of estrogen treatment and vitamin D status on differing bioavailabilities of calcium car- effect of terbinafine on pharmacokinetics and pharmacokinetics of diethylcarbamazine after bonate and calcium citrate, 1251 pharmacodynamics of desipramine in single oral dose at two different times of day healthy volunteers identified as cytochrome in human subjects, 327 evaluation of single- and multiple-dose P450 2D6 (CYP2D6) extensive metabolizers, Eletriptan epshtarromgaecnso ki(nCeetneisctsi n’ of tasbylenttsh)e:t iac slcoown-jrueglaetaesde 1211 the effects of concomitant administration of the pharmacaondk saifetny oef stingile cescsala t- estrogen replacement product, 332 theophylline and toborinone’ on ing oral doses of eletriptan, 520 plasminogen activator inhibitor-1: physiologic pharmacokinetics of both compounds in pharmacokinetics, pharmacodynamics, and role, regulation, and influence of common poor and extensive metabolizers via safety of the 5-HT1B/1D agonist eletriptan pharmacologic agents, 1187 CYP2D6, 492 following intravenous and oral administra- short-term effects of new synthetic conjugated influence of food intake and formulation on the tion, 528 estrogens on biochemical markers of bone pharmacokinetics and metabolism of Enalapril turnover, 290 bosentan, a dual endothelin receptor antagoo - a double-blind, placebo-controlled, dose-re- which studies of therapy merit credence? vita- nist, 283 sponse study of the effectiveness and safety min E and estrogen therapy as cautionary ex- lack of correlation between steady-state plasma of enalapril for children with hypertension, amples, 955 concentrations of haloperidol and 870 Ethics risperidone, 1083 Endocrine disruptors the recruitment of normal healthy volunteers: a pioglitazone: effect on CYP3A4 activity, 1299 endocrine disruptors: A new scientific role for review of the literature on use of financial in- sequential first-pass metabolism of nortilidine: clinical pharmacologists? impact on human centives, 365 the active metabolite of the synthetic opioid health, wildlife, and the environment, 7 Ethinyl estradiol drug tilidine, 1257 Endothelin receptor antagonists effect of rofecoxib on the pharmacokinetics of single plasma concentrations of 1’- hydroxymidazolam or the ratio of 1’- influence of food intake and formulation on the chronically administered oral contraceptives hydroxymidazolam:midazolam do not pre- pharmacokinetics and metabolism of in healthy female volunteers, 215 dict midazolam clearance in healthy sub- bosentan, a dual endothelin receptor antago- the influence of hormones and pharmaceutical jects, 1079 nist, 283 agents on DHEA and DHEA-S concentra- Ebastine Environmental issues tions: a review of clinical studies, 247 a double-blind, placebo-controlled study of effi- endocrine disruptors: A new scientific role for Everolimus cacy and safety of ebastine 20 mg once daily clinical pharmacologists? impact on human differential influence of two cyclosporine formu- given with and without food in treatment of health, wildlife, and the environment, 7 lations on everolimus pharmacokinetics: a seasonal allergic rhinitis, 1097 Epilepsy clinically relevant pharmacokinetic interac- Education tion, 95 clinical pharmacology: drugs as a benefit and/or advanced science education in the regulatory risk in sudden unexpected death in epi- pharmacokinetic and pharmacodynamic assess- arena: The Center for Drug Evaluation and lepsy?, 123 ments of HMG-CoA reductase inhibitors Research experience at the FDA, 711 when coadministered with everolimus, 222 multiple-dose, linear, dose-proportional development of innovative teaching materials: pharmacokinetics of retigabine in healthy Exercise-induced asthma clinical pharmacology problem-solving volunteers, 175 the new phosphodiesterase 4 inhibitor (CPPS) units: comparison with patient-ori- roflumilast is efficacious in exercise-induced ented problem-solving units and problem- pharmacoepidemiologic investigation of asthma and leads to suppression of LPS-stim- based learning, 477 clonazepam relative clearance by mixed-ef- ulated TNF-a ex vivo, 297 fect modeling using routine clinical educational issues in clinical pharmacology: pharmacokinetic data in Japanese patients, Fexofenadine who are our audiences and what are their 81 fexofenadine transport in Caco-2 cells: inhibition specialized needs?: understanding the role of veterinary medicine in public health, 718 Epinephrine with verapamil and ritonavir, 1269 an introduction to clinical research and drug de- the influence of hormones and pharmaceutical Fibrinolytic balance velopment for pharmacy and pharmacology agents on DHEA and DHEA-S concentra- plasminogen activator inhibitor-1: physiologic graduate students, 867 tions: a review of clinical studies, 247 role, regulation, and influence of common Elderly patients Eptifibatide pharmacologic agents, 1187 effects of celecoxib and diclofenac on blood pres- bleeding associated with eptifibatide targeting Fiduxosin sure, renal function, and vasoactive higher risk patients with acute coronary syn- single- and multiple-dose pharmacokinetics of prostanoids in young and elderly subjects, dromes: incidence and multivariate risk fac- fiduxosin under nonfasting conditions in 985 tors, 1366 healthy male subjects, 540

ebook img

Journal of Clinical Pharmacology 2002: Vol 42 Index PDF

21 Pages·2002·6.6 MB·English
by  
#periodicals #sim_microfilm #pub_journal-of-clinical-pharmacology
Save to my drive
Quick download
Download
Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Journal of Clinical Pharmacology 2002: Vol 42 Index

Gotschall RR, 24 Hust R, 1002 Knebel N, 175 Martin B, 7S Grafe E-U, 731 Knupp C, 419, 791 Martin BR, 20S Graham S, 558 Igel M, 835 Kohlert C, 731 Martin JM, 1147 Granneman GR, 540 Ikura-Morii M, 1275 Kohno K-l, 782 Martin PD, 1116, 1352 Grant EM, 928 Imano H, 806 Komamura K, 342 Martinez MN, 620 Grant I, 48S Innocencion G, 267 Kondo T, 1083, 1335 Martinez-Tobed A, 1303 Greenblatt DJ, 376, 1142, 1269 Inoue Y, 1083 Konsil J, 52 Marz RW, 731 Greenhalgh C, 520 Ishii Y, 1020 Koren G, Matsuda K, 151 Gross J, 403 Iyer GR, 428 Korn SH, 61 Matsuki S, 1020, 1159 Gruber AJ, 41S Kornhauser D, 1326 Matsumoto K, 342 Guan X, 899 Jaber LA, 89, 1299 Kornhauser DM, 738 Matsumoto N, 151 Gupta SK, 1109 Jacobs S, 1109 Kotegawa T, 183, 1159 Matsuno H, 782 Gutierrez M, 157 Jaehde U, 762 Kourides I, 651 McCauley J, 798 Guzzo CA, 1122 Jahnchen E, 1257 Kovarik JM, 95, 222 McCune JM, 82S Jain A, 798 Kozawa O, 782 McLeod HL, 412 Hajda JP, 1257 James GC, 528 Krahmer N, 920 McMasters K, 774 Hampel F Jr, 1097 Jann MW, 1165 Krzyzanski W, 501 Mechoulam R, 11S Haney M, 34S Jansat JM, 1303 Kulawy , 376 Medve R, 24 Harari D, 1134 Janssens L, 1341 Kuranari M, 1159 Mehlisch DR, 904 Hardman T, 1358 Jasti BR, 327 Kuroda T, 81 Merz M, 312 Hardman TC, 887 Jayawardena S, 912 Kurokawa N, 1374 Messig M, 651 Harmatz JS, 1142 Jenkins JM, 887 Kutz K, 283 Metz DC, 512 Harris SC, 520 Jenkins VC, 528 Kuwahara S, 806 Meyerrose GE, 1187 Harrison F, 605 Jesussek B, 1262 Kuye O, 444 Middleton M, 774 Harrison LI, 1134 Johnson FK, 1089 Mihara K, 1083, 1335 Hartman R, 558 Jones RT, 58S Lane A, 1147 Milton KA, 528 Hartmann S, 222 Junge K, 995 Lantz MV, 304 Mirani A, 644 Hashibe M, 103S Jusko WJ, 501 Lasseter KC, 1122, 1341 Miyamoto G, 492, 1318 Hashiguchi M, 151 Lathers CM, 7, 123, 477, 587, 718, 846 Miyatake K, 342 Hashimoto H, 1275 Kaido M, 1374 Lau CBS, 30 Moller-Pedersen J, 1262 Hashimoto H, 342 Kalbag J, 95 Lau H, 1341 Mondick J, 1326 Hatzelmann A, 297 Kamakura S, 342 Laurent A, 774 Mondick JT, 738 Hebert SJ, 82S Kanamaru M, 782 Lazarus HM, 395 Money D, 267 Hein DW, 613 Kaneko S, 1083, 1335 Leclerc V, 297 Moore BA, 28S Hejmanowski LG, 461 Kanitra L, 1011 Leeder JS, 24 Moore R, 1011 Heller HJ, 1251 Karafilidis J, 662 Lefévre G, 1147 Morganroth J, 520, 558 Hellriegel ET, 205, 450 Kashuba ADM, 376, 1079 Lehtonen L, 43 Morimoto T, 183, 1159 Hermann R, 995 Katneni K, 670 Leung A, 70 Morisaki T, 1374 Herrera P, 870 Kato H, 782 Levine M, 475 Moriya M, 1374 Herrlinger C, 985 Kato R, 1275 Levine RA, 676 Muder RR, 644 Higuchi S, 81 Kato R, 806 Liao S, 24 Mullangi R, 670 Higuera-Alhino D, 82S Kaul S, 419, 791 Lichtman AH, 20S Miiller M, 403 Hino F, 151 Kawabata Y, 782 Lim J, 1097 Mulligan TE, 1011 Hirose Y, 183 Kawai M, 1275 Liston HL, 104 Muraguchi R, 1020 Ho SSS, 976 Kawai M, 806 Loebstein R, 267 Murthy BP, 569 Ho T, 267 Kearns GL, 24, 1089 LoRusso P, 1228 Hochhaus G, 662 Kemp J, 1352 Lukacsko P, 198 Nafziger AN, 376, 1079 Holmes GB, 1089 Kemp JV, 1244 Lynch JP, 899 Nagashima S, 782 Hon YY, 1165 Kenney KB, 887 Naidu MUR, 670 Hoshaw-Woodard S, 1171 Khalsa KH, 7S Ma MK, 412 Nairn K, 1237 Hosogai Y, 151 Kim JS, 376 Ma P, 1228 Nairn K, 1244 Houle J-M, 547 King JD, 61 Ma S, 738, 1326 Nakagawa M, 1020 Hsieh JY-K, 1122 Kitani M, 492, 1318 MacArthur RD, 613 Nakamura H, 275 Huang F, 1002, 1341 Kivikko M, 43 Madani S, 1211 Nakamura K, 1020 Hubert M, 222 Klecker RW Jr, 971 Manowitz N, 1089 Nakano S, 183, 1020, 1159 Hudson JI, 41S Klein A, 1142 Marbury TC, 1109, 1311 Nakatsuka K, 1020 Huestis MA, 41S Kloft C, 762 Marcello SR, 388 Naredi P, 774 Hunt TR, 215 Klotz U, 985 Markowitz JS, 104 Nava-Ocampo AA, 37 Nelson HS, 319 Poondru S, 327 Schneck DW, 1116, 1352 Swift R, 1228 Nelson M, 205, 450 Pope HG Jr, 41S Schneider E, 995 Sy SKB, 738 Neuhauser M, 297 Porras AG, 215, 1122 Schneider W, 222 Szyjkowski RS, 676 Neuhofel AL, 461 Preston RA, 754 Schnell D, 388 Newman KB, 319 Prince WT, 887 Schraeder PL, 123 Tachibana M, 342 Nichol JM, 501 Pritchett ELC, 388 Schran H, 1228 Takahashi K, 1374 Nichola P, 419 Pruchnicki MC, 1171 Schulte MC, 388 Takahata T, 1335 Nicolau DP, 928 Schulteis G, 70 Tammara B, 492, 1318 Niecestro R, 198 Quinn J, 711 Schwartz JI, 215 Tanaka K, 1275 Nightingale C, 928 Quintiliani R, 928 Schweer H, 985 Tanaka K, 342, 806 Nishida Y, 1374 Quon CY, 1326 Schwertschlag US, 157 Tanaka T, 151 Niwa M, 782 Sciberras DG, 1122 Tashkin DP, 71S Nonaka T, 81 RaffH , 319 Scott NR, 528 Tateishi T, 100, 1335 Noveck R, 1027 Rajagopalan R, 670 Seaber E, 1237 Thomann P, 1262 Nowak SN, 89, 1299 Rance DJ, 528 Seaman J, 1228 Thomasson HR, 1219 Nwose OM, 1116 Rani UP, 670 SenderovitzT , 1262 Thyroff-Friesinger U, 403 Rao MNVS, 670 Seyberth HW, 985 Timmer W, 297 O'Day S, 774 Raoult A, 1002 Shade SB, 82S Tipping R, 1122 O’Mara E, 419 Rasty S, 577, 1366 Shader RI, 1142 Tisdale JE, 577, 1366 O’Neil WM, 613 Rauch C, 1311 Shah AK, 520 Tishler CL, 365 Ochs HR, 1142 Ravera C, 1228 Shahinfar S, 870 Tobillo E, 1109 Ohdo S, 81 Ravikanth B, 670 Shapiro R, 798 Tracey JB, 881 Ohno K, 151 Reed MD, 275 Sharma ND, 577 Trang JM, 492, 1318 Ohno M, 1374 Rehak E, 403 Shaw LM, 166 Trenk D, 1257 Ohtani Y, 183 Remple V, 267 Shaw W, 870 Troy S, 175 Ohtsuji M, 151 Richards L, 175 Shelley S, 1358 Triiten VDJ, 1142 Qie S, 1257 Ridgeway B III, 70 Shen J, 198 Truyen L, 428 Olubodun JO, 1142 Rikihisa T, 151 Shilstone J, 662 Tsikouris JP, 1187 Ono S, 1335 Rinder HM, 881 Sidney S, 64S Tsuchishita Y, 1275 Ooi K, 1275 Risch SC, 104 Siegert W, 762 Tsuchishita Y, 806 Otani Y, 1159 Robertson P Jr, 205, 450 Skerjanec A, 1228 Tsunoda SM, 376 Rocci ML Jr, 376, 1079 Slaughter RR, 89 Tsutsumi K, 183, 1159 Padhi ID, 577 Rogers JF, 1079 Smith BP, 1219 Turner M, 1165 Page RL, 388 Rohatagi SS, 1097 Smith CM, 477 Turner MB, 512 Pallotta T, 904 Romero A, 395 Smith JA, 867 Parasrampuria DA, 304 Rordorf C, 95, 222 Smith PF, 658 Uejima E, 1374 Park Y, 157 Rosenkranz B, 222 Smith T, 312 Uematsu T, 782 Parker LA, 11S Rosman H, 577 Soffer B, 870 Uemura N, 1020 Patzak U, 920 Roth MD, 71S Soffer E, 512 Uenishi K, 1275 Paul C, 1211 Rouilly M, 95 Souhrada M, 881 Ueno K, 1275 Paul G, 175 Roy P, 52, 332 Souppart C, 1147 Ueno K, 342, 806 Paul J, 512 Rushing M, 1027 Spector R, 955 Uhl K, 711 Pechstein B, 995 Spielberg SP, 24 Upmalis DH, 52 Pelland F, 267 Sack M, 1109 Srinivas NR, 670 Urae A, 151 Pentikainen PJ, 43 Sakoda S, 1374 Stevens RE, 52, 290, 332 Penzak SR, 1165 Sakuma A, 151 Stonis L, 157 van Giersbergen P, 283 Perloff MD, 1269 Salek FS, 247 Streetman DS, 376, 1079 Van Osselaer N, 1002 Peters J, 985 Salva P, 1303 Stricker W, 319 Van Peer A, 1002 Petric M, 267 Sanderson SO, 676 Strong A, 547 Vargas R, 1027 Phelps KV, 290, 332 Sandoval E, 145 Studenberg S, 887 Veit M, 731, 920 Phillips G, 198 Sarafian T, 71S Suarez JA, 1187 Velazquez-Armenta EY, 37 Pieniaszek H] Jr, 738, 1326 Sarno M, 774 Sudhop T, 835 Venkataramanan R, 644, 798 Pierre LN, 383 Sato N, 151 Sum Chow MS, 605 Verhaeghe T, 428, 1002, 1341 Pinguier J-L, 1311 Satou M, 81 Sun JX, 198 Verlinden M, 540 Pisegna JR, 512 Sauer J-M, 1219 Sutfin T, 651 Verrill SS, 52 Pittenger AL, 1109 Schindler G, 731, 920 Suzuki A, 1083 Vescio R, 1228 Poindexter JR, 1251 Schlamm H, 395 Svensson CK, 613 Vesell ES, 955 Pollack GM, 569 Schmidli H, 1147 Swan SK, 1109 Victory JM, 461 Vincenti FG, 304 Westervelt P, 412 Wood CC, 881 Yoshida Y, 782 von Bergmann K, 835 Wetzler M, 501 Wurst W, 297 Yoshimura H, 1275 von Moltke LL, 1142 White CM, 963 Yuan C-S, 899 von Moltke LL, 1269 Whitman E, 774 Xu J, 157 Yukawa E, 81 von Nieciecki A, 920 Wilcox DF, 711 Yukawa M, 81 Wilding I, 1200 Yaksh TL, 70 Yurgelun-Todd D, 41S Walden C, 1027 Wilkinson GR, 376, 1079 Yamazaki K, 151 Wallace AW, 437 Wilkinson WE, 388 Yan J-H, 419 Zhang Y, 540 Wallace MS, 70 Wilner KD, 1027 Yanagihara T, 1374 Zhang Z, 870 Wang C, 881 Wilson JT, 24 Yanase K, 151 Zhang Z-F, 103S Wang Y, 1211 Wilton JH, 461 Yanovich S, 395 Zhao Q, 428, 1002, 1341 Ward C, 1147 Winchell GA, 61 Yasui-Furukori N, 100, 1083, 1335 Zhi J, 1011 Warwick MJ, 1116, 1352 Witcher JW, 1219 Yates R, 1237 Zuo Z, 605 Wei GCG, 444 Wittig J, 920 Yates R, 1244 Weidekamm E, 283 Woloski M, 267 Yazaki A, 151 Wells T, 870 Wong PH, 215 Yonezawa E, 342, 806 Subject Index, Volume 42 (2002) ACE inhibitors progressive cholestatic liver disease associated pharmacokinetics and safety of galantamine in comparative effects on dynamic renal potassium with clarithromycin treatment, 676 subjects with hepatic impairment and excretion of ACE inhibition vs angiotensin Age healthy volunteers, 428 receptor blockade in hypertensive patients clinical pharmacokinetics of verteporfin, 547 Amifostine with type II diabetes mellitus, 754 cyclobenzaprine pharmacokinetics, including new dosing regimens for amifostine: a pilot study a double-blind, placebo-controlled, dose-re- effects of age, gender, and hepatic insuffi- to compare the relative bioavailability of oral sponse study of the effectiveness and safety ciency, 61 and subcutaneous administration with intra- of enalapril! for children with hypertension, no effect of age or gender on pharmacokinetics of venous infusion, 166 870 rosuvastatin: a new HMG-CoA reductase in- Aminoglutethimide plasminogen activator inhibitor-1: physiologic hibitor, 1116 role, regulation, and influence of common the influence of hormones and pharmaceutical pharmacologic agents, 1187 Age-related macular degeneration agents on DHEA and DHEA-S concentra- Acetylator phenotype clinical pharmacokinetics of verteporfin, 5 c= N tions: a review of clinical studies, 247 Alcohol Amiodarone acetylator phenotype and genotype in HIV-in- fected patients with and without sulfona- the influence of hormones and pharmaceutical lack of interaction between amiodarone and mide hypersensitivity, 613 agents on DHEA and DHEA-S concentra- mexiletine in cardiac arrhythmia patients, Acute myeloid leukemia tions: a review of clinical studies, 247 342 pharmacodynamic modeling of thrombopoietin, Alfentanil Amitriptyline platelet, and megakaryocyte dynamics in pa- concentration-effect relationships for intrave- the influence of hormones and pharmaceutical tients with acute myeloid leukemia undergo- nous alfentanil and ketamine infusions in agents on DHEA and DHEA-S concentra- ing dose intensive chemotherapy, 501 human volunteers: effects on acute thresh- tions: a review of clinical studies, 247 olds and capsaicin-evoked hyperpathia, 70 Acute myocardial infarction (AMI) pharmacokinetic evaluation of possible interac- Alfuzosin plasminogen activator inhibitor-1: physiologic tion between selected concomitant medica- role, regulation, and influence of common pharmacokinetics and safety of a single oral dose tions and orlistat at steady state in healthy pharmacologic agents, 1187 of once-daily alfuzosin, 10 mg, in male sub- subjects, 1011 jects with mild to severe renal impairment, Adolescents Ampicillin 1311 adolescents prenatally exposed to marijuana: ex- Allergic rhinitis the influence of hormones and pharmaceutical amination of facets of complex behaviors and agents on DHEA and DHEA-S concentra- comparisons with the influence of in utero a double-blind, placebo-controlled study of effi- tions: a review of clinical studies, 247 cigarettes, 97S cacy and safety of ebastine 20 mg once daily given with and without food in treatment of Amprenavir Adrenal androgoe ns seasonal allergic rhinitis, 1097 pharmacokinetics of GW433908, a prodrug of the influence of hormones and pharmaceutical a new solution-based intranasal triamcinolone amprenavir, in healthy male volunteers, 887 atigoennst:s a orne viDewH EAof clainndi calD HsEtuAd-iSes , c2o4n7c entra- arceentnioanli de alfloerrgmiucl atirohinn itiins : pathioewnt s dwoietsh tphee- Analgesic agents Adrenergic blocking agents pharmacokinetic/pharmacodynamic profile comparison of the pharmacokinetics of the aignefnltuse ncoen ofD HhEoAr monaends DanHdE A-phSa rmcaocnecuetnitcraal- afoqru ecoourst isoslu spseunpspiroens-sbiaosne d cofmorpmaurlea tiowni,t h 66a2n ofoxrymcuoldaotnioen s,a dm1i9n2 istered in three Percocet tions: a review of clinical studies, 247 Almotriptan concentration-effect relationships for intrave- nous alfentanil and ketamine infusions in a-1-Adrenoreceptor antagonists absolute bioavailability, pharmacokinetics, and human volunteers: effects on acute thresh- urinary excretion of the novel antimigraine single- and multiple-dose pharmacokinetics of olds and capsaicin-evoked hyperpathia, 70 agent almotriptan in healthy male volun- fiduxosin under nonfasting conditions in healthy male subjects, 540 teers, 1303 contribution of morphine-6-glucuronide to Alpha-tocopherol antinociception following intravenous ad- Adrenocorticotropin ministration of morphine to healthy volun- the influence of hormones and pharmaceutical the influence of hormones and pharmaceutical teers, 569 agents on DHEA and DHEA-S concentra- agents on DHEA and DHEA-S concentra- tions: a review of clinical studies, 247 a controlled comparative study of ibuprofen tions: a review of clinical studies, 247 arginate vs conventional ibuprofen in treat- Alprazolam Adverse events ment of postoperative dental pain, 904 the influence of hormones and pharmaceutical bleeding associated with eptifibatide targeting agents on DHEA and DHEA-S concentra- efficacy and tolerability of nonprescription higher risk patients with acute coronary syn- ibuprofen vs celecoxib for dental pain, 912 tions: a review of clinical studies, 247 dromes: incidence and multivariate risk fac- tors, 1366 Alzheimer’s disease miniomxaylc odionntee,ra ct9i2o8n between gatifloxacin and hypotension and bradycardia in a healthy volun- electrocardiographic effects of rivastigmine, 558 teer following a single 5 mg dose of galantamine pharmacokinetics, safety, and transcutaneous electrical acupoint stimulation olanzapine, 104 tolerability profiles are similar in healthy potentiates analgesic effect of morphine, 899 microsomal enzyme induction and clinical ag- caucasian and Japanese subjects, 1002 Angiotensin receptor blockers (ARB) gravation of porphyria: the evaluation of hu- pharmacokinetic and safety assessments of comparative effects on dynamic renal potassium man urinary 6B-hydroxycortisol/cortisol ra- galantamine and risperidone after the two excretion of ACE inhibition vs angiotensin tio as the index of hepatic CYP3A4 activity, drugs are administered alone and together, receptor blockade in hypertensive patients 1374 1341 with type II diabetes mellitus, 754 Animals Antidepressants Antilipemic agents endocrine disruptors: A new scientific role for effect of terbinafine on pharmacokinetics and the influence of hormones and pharmaceutical clinical pharmacologists? impact on human pharmacodynamics of desipramine in agents on DHEA and DHEA-S concentra- health, wildlife, and the environment, 7 healthy volunteers identified as cytochrome tions: a review of clinical studies, 247 Antiarrhythmic drugs P450 2D6 (CYP2D6) extensive metabolizers, Antimalarial drugs effects of azimilide on heart rate and ECG con- 1211 interaction trial between artemether-lumefantrine duction intervals during sinus rhythm in pa- the influence of hormones and pharmaceutical (Riamet’) and quinine in healthy subjects, tients with a history of atrial fibrillation, 388 agents on DHEA and DHEA-S concentra- 1147 lack of interaction between amiodarone and tions: a review of clinical studies, 247 Antimicrobial drugs mexiletine in cardiac arrhythmia patients, Antidiabetic agents clinical pharmacology of antimicrobial use in hu- 342 insulin-metformin combination therapy in obese mans and animals, 587 Anti-arthritis drugs patients with type 2 diabetes, 89 Antinociception celecoxib does not affect the antiplatelet activity lack of effect of sucralfate on absorption and of aspirin in healthy volunteers, 1027 pharmacokinetics of rosiglitazone, 670 contribution of morphine-6-glucuronide to antinociception following intravenous ad- effect of rofecoxib on the pharmacokinetics of no effect of the novel antidiabetic agent ministration of morphine to healthy volun- chronically administered oral contraceptives nateglinide on pharmacokinetics and antico- teers, 569 in healthy female volunteers, 215 agulant properties of warfarin in healthy vol- Antiparasitic drugs effects of celecoxib and diclofenac on blood pres- unteers, 1358 sure, renal function, and vasoactive safety, tolerability, and pharmacokinetics of esca- prostanoids in young and elderly subjects, pharmacokinetics and pharmacodynamics of ex- lating high doses of ivermectin in healthy 985 twietnhd edi-mrmeeldeiaastee -reglleiapiszei dgel ipGiIzTidSe icno mpaptaireentds adult subjects, 1122 effects of meloxicam on platelet function in with type II diabetes mellitus, 651 Antipsychotic agents healthy adults: a randomized, double-blind, pioglitazone: effect on CYP3A4 activity, 1299 hypotension and bradycardia in a healthy volun- placebo-controlled trial, 881 teer following a single 5 mg dose of efficacy and tolerability of nonprescription Antiepileptic drugs olanzapine, 104 ibuprofen vs celecoxib for dental pain, 912 clinical pharmacology: drugs as a benefit and/or lack of correlation between steady-state plasma Antibiotics risk in sudden unexpected death in epi- concentrations of haloperidol and clinical pharmacology of antimicrobial use in hu- lepsy?, 123 risperidone, 1083 mans and animals, 587 multiple-dose, linear, dose-proportional Antiretroviral drugs pharmacokinetics of retigabine in healthy comparative target site pharmacokinetics of im- effect of food on the pharmacokinetics of (-) and volunteers, 175 mediate- and modified-release formulations (+) dOTC when administered as an oral of cefaclor in humans, 403 pharmacoepidemiologic investigation of racemate, 658 clonazepam relative clearance by mixed-ef- the effect of erythromycin and clarithromycin on pharmacokinetics of GW433908, a prodrug of fect modeling using routine clinical pharmacokinetics of intravenous digoxin in amprenavir, in healthy male volunteers, 887 healthy volunteers, 1159 8p1h armacokinetic data in Japanese patients, Antithrombotic agents impairment of ciprofloxacin absorption by cal- cium polycarbophil, 806 Antifungal agents safety, pharmacokinetics, and time course of pharmacologic response of the active metab- the influence of hormones and pharmaceutical effect of terbinafine on pharmacokinetics and olite of roxifiban, XV459, a glycoprotein IIb/ agents on DHEA and DHEA-S concentra- pharmacodynamics of desipramine in Illa antagonist, following oral administration tions: a review of clinical studies, 247 healthy volunteers identified as cytochrome in healthy volunteers, 738 lack of bioequivalence of ciprofloxacin when ad- P450 2D6 (CYP2D6) extensive metabolizers, Antituberculosis chemotherapy ministered with calcium-fortified orange 1211 juice: a new twist on an old interaction, 461 safety and pharmacokinetics of oral voriconazole a simplified method for detecting isoniazid com- in patients at risk of fungal infection: a dose pliance in patients receiving antituberculosis minimal interaction between gatifloxacin and escalation study, 395 chemotherapy, 151 oxycodone, 928 pharmacokinetics of cefoperazone and Antihistamines Anxiolytic agents effect of fluconazole on the pharmacokinetics sulbactam in liver transplant patients, 644 a double-blind, placebo-controlled study of effi- progressive cholestatic liver disease associated cacy and safety of ebastine 20 mg once daily abnrdo mapzheapramma:c odayn naampipclsic atoifo no raol f aenlde ctrreocetna-l with clarithromycin treatment, 676 gsievaesnon awli tha llaenrgdi c wirthhinoiutti s, fo1o0d9 7i n treatment of cephalography as the pharmacodynamic a study of the interaction potential of method, 183 azithromycin and clarithromycin with fexofenadine transport in Caco-2 cells: inhibition Arbutin atorvastatin in healthy volunteers, 444 with verapamil and ritonavir, 1269 urinary excretion and metabolism of arbutin after Anticoagulation Antihypertensive drugs oral administration of Arctostaphylos uvae effect of modafinil at steady state on the single- comparative effects on dynamic renal potassium ursi extract as film-coated tables and aqueous dose pharmacokinetic profile of warfarin in excretion of ACE inhibition vs angiotensin solution in healthy humans, 920 healthy volunteers, 205 receptor blockade in hypertensive patients Artemether-lumefantrine increased sensitivity to warfarin in elderly His- with type II diabetes mellitus, 754 interaction trial between artemether-lumefantrine panics, 145 a double-blind, placebo-controlled, dose-re- (Riamet’) and quinine in healthy subjects, no effect of the novel antidiabetic agent sponse study of the effeciiveness and safety 1147 nateglinide on pharmacokinetics and antico- of enalapril for children with hypertension, agulant properties of warfarin in healthy vol- 870 Arterial elasticity unteers, 1358 effect of doxazosin on arterial elasticity: func- effect of doxazosin on arterial elasticity: func- Anticonvulsants tional vs structural changes, 1105 tional vs structural changes, 1105 the influence of hormones and pharmaceutical plasminogen activator inhibitor-1: physiologic Aspirin agents on DHEA and DHEA-S concentra- role, regulation, and influence of common celecoxib does not affect the antiplatelet activity tions: a review of clinical studies, 247 pharmacologic agents, 1187 of aspirin in healthy volunteers, 1027 Asthma Benzodiazepines drugs are administered alone and together. bioavailability and metabolism of mometasone effect of dietary fat content in meals on 1341 furoate: pharmacology vs methodology, 383 pharmacokinetics of quazepam, 1335 sequential first-pass metabolism of nortilidine: a comparison of methods for assessing hypotha- effect of fluconazole on the pharmacokinetic: the active metabolite of the synthetic opioid lamic-pituitary-adrenal (HPA) axis activity in and pharmacodynamics of oral and rectal drug tilidine, 1257 asthma patients treated with inhaled bromazepam: an application of electroen- systemic availability and pharmacokinetics of corticosteroids, 319 cephalography as the pharmacodynamic thymol in humans, 731 the new phosphodiesterase 4 inhibitor method, 183 Bioequivalence roflumilast is efficacious in exercise-induced the influence of hormones and pharmaceutical bioequivalence of two formulations of didanosine, asthma and leads to suppression of LPS-stim- agents on DHEA and DHEA-S concentra- encapsulated enteric-coated beads and buf- ulated TNF-a ex vivo, 297 tions: a review of clinical studies, 247 fered tablet, in healthy volunteers and HIV- Atherosclerosis limited sampling strategy to predict AUC of the infected subjects, 791 clinical manifestation of atherosclerotic periph- CadYuPlt3sA: apphpelnicoattyipoinn g to prvoabreio usm idaaszsoayl amt echi-n bioeqtueistvianlaeln ce prtoedsuticntgs : forw hlaotca llyr olaec tinfogr gagsatrmomina- terraela tamretnetri alo f diinsteearsmei ttaenndt rcollae udoifc actiiloosnt,a zo1l2 91i n niques, 376 scintigraphy?, 1200 Beta-adrenoreceptor antagonists an evaluation of bioequivalence of two 7-day Atomoxetine pharmacokinetic and pharmacodynamic differ- 178-estradiol transdermal delivery systems effect of potent CYP2D6 inhibition by paroxetine ences between ocular and nasal installation by anatomical site, 1134 on atomoxetine pharmacokinetics, 1219 of carteolol on intraocular pressure and heart lack of bioequivalence of ciprofloxacin when ad- Atorvastatin triavtiet y,i n 1J0a2p0a nese men with high CYP2D6 ac- ministered with calcium-fortified orange pharmacokinetic and pharmacodynamic assess- juice: a new twist on an old interaction, 461 ments of HMG-CoA reductase inhibitors Beta-lactam antibiotics Biotransformation when coadministered with everolimus, 222 comparative target site pharmacokinetics of im- concordance between tramadol and pharmacokinetic evaluation of possible interac- mediate- and modified-release formulations dextromethorphan parent/metabolite ratios: tion between selected concomitant medica- of cefaclor in humans, 403 the influence of CYP2D6 and non-CYP2D6 tions and orlistat at steady state in healthy Beta-lactamase inhibitor pathways on biotransformation, 24 subjects, 1011 pharmacokinetics of cefoperazone and Bisphosphonates a study of the interaction potential of sulbactam in liver transplant patients, 644 pharmacokinetics and pharmacodynamics of azithromycin and clarithromycin with Bioavailability zoledronic acid in cancer patients with bone atorvastatin in healthy volunteers, 444 absolute bioavailability, pharmacokinetics, and metastases, 1228 Attention-deficit hyperactivity disorder (ADHD) urinary excretion of the novel antimigraine Bleeding effect of potent CYP2D6 inhibition by paroxetine agent almotriptan in healthy male volun- bleeding associated with eptifibatide targeting on atomoxetine pharmacokinetics, 1219 teers, 1303 higher risk patients with acute coronary syn- pemoline ingestion in children: a report of five bioavailability and metabolism of mometasone dromes: incidence and multivariate risk fac- cases and review of the literature, 275 furoate: pharmacology vs methodology, 383 tors, 1366 Autonomic drugs bioavailability study of a1 200 mg miconazole ni- Blood pressure trate vaginal ovule in healthy female adults, the influence of hormones and pharmaceutical 52 effects of celecoxib and diclofenac on blood pres- agents on DHEA and DHEA-S concentra- sure, renal function, and vasoactive tions: a review of clinical studies, 247 comparative pharmacokinetics of lovastatin ex- prostanoids in young and elderly subjects, tended-release tablets and lovastatin imme- 985 Azimilide diate-release tablets in humans, 198 Bone metastases effects of azimilide on heart rate and ECG con- cyclobenzaprine pharmacokinetics, including duction intervals during sinus rhythm in pa- effects of age, gender, and hepatic insuffi- pharmacokinetics and pharmacodynamics of tients with a histoofr atryia l fibrillation, 388 ciency, 61 zoledronic acid in cancer patients with bone metastases, 1228 Azithromycin effect of estrogen treatment and vitamin D status on differing bioavailabilities of calcium car- Bone turnover a study of the interaction potential of azithromycin and clarithromycin with bonate and calcium citrate, 1251 short-term effects of new synthetic conjugated atorvastatin in healthy volunteers, 444 effect of food on the oral bioavailability of estrogens on biochemical markers of bone didanosine from encapsulated enteric- turnover, 290 Bearberry coated beads, 419 Bosentan urinary excretion and metabolism of arbutin after effect of phosphate binders on supplemental iron influence of food intake and formulation on the oral administration of Arctostaphylos uvae absorption in healthy subjects, 1171 pharmacokinetics and metabolism of suorlsuit eixotnr acitn ahse aflitlhmy- cohautmeadn st,a bl9es2 0 and aqueous influence of food intake and formulation on the bosentan, a dual endothelin receptor antago- pharmacokinetics and metabolism of nist, 283 Benfluorex bosentan, a dual endothelin receptor antago- Botanicals. See Herbal medicine the influence of hormones and pharmaceutical nist, 283 Breast cancer agents on DHEA and DHEA-S concentra- a mechanistic approach to understanding factors multiple-dose, safety, pharmacokinetics, and tions: a review of clinical studies, 247 affecting drug absorption, 620 pharmacodynamics of a new selective estro- Benign prostatic hypertrophy (BPH) minimal interaction between gatifloxacin and gen receptor modulator, ERA-923, in healthy pharmacokinetics and safety of as ingle oral dose oxycodone, 928 postmenopausal women, 157 of once-daily alfuzosin, 10 mg, in male sub- new dosing regimens for amifostine: a pilot study Bromazepam jects with mild to severe renal impairment, to compare the relative bioavailability of oral effect of fluconazole on the pharmacokinetics 1311 and subcutaneous administration with intra- and pharmacodynamics of oral and rectal single- and multiple-dose pharmacokinetics of venous infusion, 166 bromazepam: an application of electroen- fiduxosin under nonfasting conditions in pharmacokinetic and safety assessments of cephalography as the pharmacodynamic healthy male subjects, 540 galantamine and risperidone after the two method, 183 Bromocriptine Cannabinoids Center for Drug Evaluation and Research the influence of hormones and pharmaceutical effects of smoked marijuana in healthy and HIV+ (CDER) agents on DHEA and DHEA-S concentra- marijuana smokers, 34S advanced science education in the regulatory tions: a review of clinical studies, 247 Cannabis. See Marijuana arena: The Center for Drug Evaluation and Caco-2 cells Capsaicin Research experience at the FDA, 711 fexofenadine transport in Caco-2 cells: inhibition concentration-effect relationships for intrave- Central nervous system drugs with verapamil and ritonavir, 1269 nous alfentanil and ketamine infusions in the influence of hormones and pharmaceutical Calcineurin inhibitors human volunteers: effects on acute thresh- agents on DHEA and DHEA-S concentra- effect of calcineurin inhibitor therapy on P-gp ex- olds and capsaicin-evoked hyperpathia, 70 tions: a review of clinical studies, 247 pression and function in lymphocytes of re- Carbamazepine Cephalosporins nal transplant patients, 304 carbamazepine decreases antihypertensive effect pharmacokinetics of cefoperazone and Calcium carbonate of nilvadipine, 100 sulbactam in liver transplant patients, 644 effect of estrogen treatment and vitamin D status the influence of hormones and pharmaceutical Cetrorelix acetate on differing bioavailabilities of calcium car- agents on DHEA and DHEA-S concentra- bonate and calcium citrate, 1251 tions: a review of clinical studies, 247 novel formulations of cetrorelix acetate in Calcium channel blockers Carboplatin healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics, 995 the influence of hormones and pharmaceutical toxicity of high-dose carboplatin: ultrafiltered agents on DHEA and DHEA-S concentra- and not total plasma pharmacokinetics is of Chickenpox tions: a review of clinical studies, 247 clinical relevance, 762 serum concentrations, efficacy, and safety of a Calcium citrate Cardiovascular disease new, intravenously administered varicella effect of estrogen treatment and vitamin D status bleeding associated with eptifibatide targeting zoster immune globulin in pregnant women, on differing bioavailabilities of calcium car- higher risk patients with acute coronary syn- 267 bonate and calcium citrate, 1251 dromes: incidence and multivariate risk fac- Children. See Pediatrics Calcium polycarbophil tors, 1366 Chinese traditional medicine plasminogen activator inhibitor-1: physiologic impairment of ciprofloxacin absorption by cal- Coriolus versicolor: a medicinal mushroom with role, regulation, and influence of common cium polycarbophil, 806 promising immunotherapeutic values, 976 pharmacologic agents, 1187 impairment of mycophenolate mofetil absorp- Cardiovascular drugs hawthorn, 605 tion by calcium polycarbophil, 1275 the influence of hormones and pharmaceutical Schizonepeta tenuifolia: chemistry, pharmacol- Calcium sensitizers agents on DHEA and DHEA-S concentra- ogy, and clinical applications, 30 pharmacodynamics and safety of a new calcium tioo ns: a review of clinical studies, 247 Cholinesterase inhibitors sdeunrsiintgiz earn, elxetveonsdiemde ndinafnu,s ioann d ini tsp amteiteantbso liwtietsh Carteolol electrocardiographic effects of rivastigmine, 558 severe heart failure, 43 pharmacokinetic and pharmacodynamic differ- galantamine pharmacokinetics, safety, and ences between ocular and nasal installation Cancer of carteolol on intraocular pressure and heart tolerability profiles are similar in healthy marijuana smoking and head and neck cancer, rate in Japanese men with high CYP2D6 ac- caucasian and Japanese subjects, 1002 1038S tivity, 1020 pharmacokinetic and safety assessments of galantamine and risperidone after the two Cancer chemotherapy Cefaclor drugs are administered alone and together, Coriolus versicolor: a medicinal mushroom with comparative target site pharmacokinetics of im- 1341 promising immunotherapeutic values, 976 mediate- and modified-release formulations pharmacodynamic modeling of thrombopoietin, of cefaclor in humans, 403 pharsmuabcjoekcitnse tiwcist h anhde psaatfiect y iofm pgaailramnteanmti nea nidn platelet, and megakaryocyte dynamics in pa- Cefodizime healthy volunteers, 428 tients with acute myeloid leukemia undergo- the influence of hormones and pharmaceutical ing dose intensive chemotherapy, 501 agents on DHEA and DHEA-S concentra- Choroidal neovascularization pharmacokinetic study of infusional valspodar, tions: a review of clinical studies, 247 clinical pharmacokinetics of verteporfin, 547 412 Cefoperazone Chronic obstructive pulmonary disease (COPD) toxicity of high-dose carboplatin: ultrafiltered pharmacokinetics of cefoperazone and the new phosphodiesterase 4 inhibitor and not total plasma pharmacokinetics is of sulbactam in liver transplant patients, 644 roflumilast is efficacious in exercise-induced clinical relevance, 762 Celecoxib asthma and leads to suppression of LPS-stim- Cancer patients celecoxib does not affect the antiplatelet activity ulated TNF-o ex vivo, 297 pharmacokinetics and pharmacodynamics of of aspirin in healthy volunteers, 1027 Chronotherapy zoledronic acid in cancer patients with bone effects of celecoxib and diclofenac on blood pres- pharmacokinetics of diethylcarbamazine after metastases, 1228 sure, renal function, and vasoactive single oral dose at two different times of day pharmacokinetics of histamine dihydrochloride prostanoids in young and elderly subjects, in human subjects, 327 in healthy volunteers and cancer patients: 985 implications for combined immunotherapy Cilostazol with interleukin-2, 774 efficiabcuyp roafnedn vtso lceerlaebciolxiitby foofr dneontnaplr espacirni,p t9i1o2 n clinical manifestation of atherosclerotic periph- Candesartan eral arterial disease and role of cilostazol in Cenestin treatment of intermittent claudication, 1291 comparative effects on dynamic renal potassium evaluation of single- and multiple-dose excretion of ACE inhibition vs angiotensin pharmacokinetics of synthetic conjugated Ciprofloxacin receptor blockade in hypertensive patients estrogens (Cenestin’ tablets): a slow-release impairment of ciprofloxacin absorption by cal- with type II diabetes mellitus, 754 estrogen replacement product, 332 cium polycarbophil, 806 Cannabidiol short-term effects of new synthetic conjugated lack of bioequivalence of ciprofloxacin when ad- cannabidiol: an overview of some pharmacologi- estrogens on biochemical markers of bone ministered with calcium-fortified orange cal aspects, 11S turnover, 290 juice: a new twist on an old interaction, 461 1387 Clarithromycin Co-artemether tions and orlistat at steady state in healthy the effect of erythromycin and clarithromycin on interaction trial between artemether-lumefantrine subjects, 1011 pharmacokinetics of intravenous digoxin in (Riamet’) and quinine in healthy subjects, CYP3A4 healthy volunteers, 1159 1147 limited sampling strategy to predict AUC of the progressive cholestatic liver disease associated Compliance CYP3A phenotyping probe midazolam in with clarithromycin treatment, 676 a simplified method for detecting isoniazid com- adults: application to various assay tech- a study of the interaction potential of pliance in patients receiving antituberculosis niques, 376 azithromycin and clarithromycin with chemotherapy, 151 microsomal enzyme induction and clinical ag- atorvastatin in healthy volunteers, 444 Congestive heart failure gravation of porphyria: the evaluation of hu- Clearance. See Drug clearance the effects of concomitant administration of man urinary 6$-hydroxycortisol/cortisol ra- theophylline and _ toborinone’ on tio as the index of hepatic CYP3A4 activity, Clinical practice guidelines pharmacokinetics of both compounds in 1374 valuing knowledge and the knowledge of values: poor and extensive metabolizers via pioglitazone: effect on CYP3A4 activity, 1299 uscnrdiebrinsgt,a n4d7i5n g guideline-incongruent pre- CYP2D6, 492 Cystitis pharmacokinetics of toborinone in subjects with Clinical studies congestive heart failure and concomitant re- urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae clinical pharmacology: drugs as a benefit and/or nal impairment and/or concomitant hepatic ursi extract as film-coated tables and aqueous risk in sudden unexpected death in epi- impairment, 1318 solution in healthy humans, 920 lepsy?, 123 Conjugated estrogens Cytochrome P450 a double-blind, placebo-controlled study of effi- evaluation of single- and multiple-dose pharma- cacy and safety of ebastine 20 mg once daily cokinetics of synthetic conjugated estrogens concordance between tramadol and given with and without food in treatment of (Cenestin® tablets): a slow-release estrogen re- dextromethorphan parent/metabolite ratios: seasonal allergic rhinitis, 1097 placement product, 332 the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation, 24 effect of doxazosin on arterial elasticity: func- short-term effects of new synthetic conjugated tional vs structural changes, 1105 estrogens on biochemical markers of bone effect of potent CYP2D6 inhibition by paroxetine evaluation of renal function in transplant pa- turnover, 290 on atomoxetine pharmacokinetics, 1219 tients on tacrolimus therapy, 798 Corticosteroids effect of terbinafine on pharmacokinetics and the influence of hormones and pharmaceutical bioavailability and metabolism of mometasone pharmacodynamics of desipramine in agents on DHEA and DHEA-S concentra- furoate: pharmacology vs methodology, 383 healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers, tions: a review of clinical studies, 247 a comparison of methods for assessing hypotha- 1211 insulin-metformin combination therapy in obese lamic-pituitary-adrenal (HPA) axis activity in patients with type 2 diabetes, 89 asthma patients treated with inhaled Cytokine monotherapy corticosteroids, 319 pharmacokinetics of histamine dihydrochloride an introduction to clinical research and drug de- velopment for pharmacy and pharmacology Corticotropin-releasing hormone in healthy volunteers and cancer patients: graduate students, 867 the influence of hormones and pharmaceutical implications for combined immunotherapy agents on DHEA and DHEA-S concentra- with interleukin-2, 774 serum concentrations, efficacy, and safety of a new, intravenously administered varicella tions: a review of clinical studies, 247 Cytoprotective drugs zoster immune globulin in pregnant women, COX-2 inhibitors new dosing regimens for amifostine: a pilot study 267 celecoxib does not affect the antiplatelet activity to compare the relative bioavailability of oral which studies of therapy merit credence? vita- of aspirin in healthy volunteers, 1027 and subcutaneous administration with intra- min E and estrogen therapy as cautionary ex- effect of rofecoxib on the pharmacokinetics of venous infusion, 166 amples, 955 chronically administered oral contraceptives Danazol which studies of therapy merit credence? vita- in healthy female volunteers, 215 the influence of hormones and pharmaceutical min E and estrogen therapy as cautionary ex- effects of celecoxib and diclofenac on blood pres- agents on DHEA and DHEA-S concentra- amples, 955 sure, renal function, and vasoactive tions: a review of clinical studies, 247 Clinical trials prostanoids in young and elderly subjects, Dehydroepiandrosterone (DHEA) 985 HIV testing in early clinical trials: who should the influence of hormones and pharmaceutical effects of meloxicam on platelet function in decide whether it is warranted?, 601 agents on DHEA and DHEA-S concentra- healthy adults: a randomized, double-blind, the recruitment of normal healthy volunteers: a placebo-controlled trial, 881 tions: a review of clinical studies, 247 review of the literature on use of financial in- Dental pain efficacy and tolerability of nonprescription centives, 365 ibuprofen vs celecoxib for dental pain, 912 a controlled comparative study of ibuprofen Clomiphene Cyclobenzaprine arginate vs conventional ibuprofen in treat- the influence of hormones and pharmaceutical cyclobenzaprine pharmacokinetics, including ment of postoperative dental pain, 904 agents on DHEA and DHEA-S concentra- effects of age, gender, and hepatic insuffi- efficacy and tolerability of nonprescription tions: a review of clinical studies, 247 ciency, 61 ibuprofen vs celecoxib for dental pain, 912 Clomipramine Cyclosporine Desipramine the influence of hormones and pharmaceutical differential influence of two cyclosporine formu- effect of terbinafine on pharmacokinetics and agents on DHEA and DHEA-S concentra- lations on everolimus pharmacokinetics: a pharmacodynamics of desipramine in tions: a review ofc linical studies, 247 clinically relevant pharmacokinetic interac- healthy volunteers identified as cytochrome Clonazepam tion, 95 P450 2D6 (CYP2D6) extensive metabolizers, pharmacoepidemiologic investigation of effect of calcineurin inhibitor therapy on P-gp ex- 1211 clonazepam relative clearance by mixed-ef- pression and function in lymphocytes of re- Dexamethasone fect modeling using routine clinical nal transplant patients, 304 the influence of hormones and pharmaceutical pharmacokinetic data in Japanese patients, pharmacokinetic evaluation of possible interac- agents on DHEA and DHEA-S concentra- 81 tion between selected concomitant medica- tions: a review of clinical studies, 247 Dextroamphetamine Doxazosin effect of phosphate binders on supplemental iron steady-state pharmacokinetics and tolerability of effect of doxazosin on arterial elasticity: func- absorption in healthy subjects, 1171 modafinil administered alone or in combina- tional vs structural changes, 1105 effect of potent CYP2D6 inhibition by paroxetine tion with dextroamphetamine in healthy vol- Drug absorption on atomoxetine pharmacokinetics, 1219 unteers, 450 impairment of ciprofloxacin absorption by cal- effect of rofecoxib on the pharmacokinetics of Dextromethorphan cium polycarbophil, 806 chronically administered oral contraceptives in healthy female volunteers, 215 concordance between tramadol and lack of effect of sucralfate on absorption and dextromethorphan parent/metabolite ratios: pharmacokinetics of rosiglitazone, 670 effect of seville orange juice and grapefruit juice the influence of CYP2D6 and non-CYP2D6 on indinavir pharmacokinetics, 1165 a mechanistic approach to understanding factors pathways on biotransformation, 24 affecting drug absorption, 620 effect of terbinafine on pharmacokinetics and Diabetes mellitus pharmacodynamics of desipramine in Drug abuse. See Marijuana healthy volunteers identified as cytochrome comparative effects on dynamic renal potassium excretion of ACE inhibition vs angiotensin Drug binding P450 2D6 (CYP2D6) extensive metabolizers, receptor blockade in hypertensive patients evaluation of highly bound drugs: interspecies, 1211 with type II diabetes mellitus, 754 intersubject, and related comparisons, 971 the effects of concomitant administration of insulin-metformin combination therapy in obese Drug clearance theophylline and toborinone’ on pharmacokinetics of both compounds in patients with type 2 diabetes, 89 pharmacoepidemiologic investigation of poor and extensive metabolizers via lack of effect of sucralfate on absorption and clonazepam relative clearance by mixed-ef- CYP2D6, 492 pharmacokinetics of rosiglitazone, 670 fect modeling using routine clinical pharmacokinetic data in Japanese patients, fexofenadine transport in Caco-2 cells: inhibition no effect of the novel antidiabetic agent with verapamil and ritonavir, 1269 61 nateglinide on pharmacokinetics and antico- agulant properties of warfarin in healthy vol- single plasma concentrations of 1’- impaciirumme ntp olyofc arcbiporpohfillo,x a8c0i6n absorption by cal- unteers, 1358 hydroxymidazolam or the ratio of 1’- hydroxymidazolam:midazolam do not pre- impairment of mycophenolate mofetil absorp- pharmacokinetics and pharmacodynamics of ex- dict midazolam clearance in healthy sub- tion by calcium polycarbophil, 1275 tended-release glipizide GITS compared jects, 1079 with immediate-release glipizide in patients the influence of hormones and pharmaceutical with type II diabetes mellitus, 651 Drug dependency agents on DHEA and DHEA-S concentra- development and consequences of cannabis de- tions: a review of clinical studies, 247 pioglitazone: effect on CYP3A4 activity, 1299 pendence, 28S interaction trial between artemether-lumefantrine Diclofenac effects of smoked marijuana in healthy and HIV+ (Riamet’) and quinine in healthy subjects, effects of celecoxiabnd diclofenac on blood pres- marijuana smokers, 34S 1147 sure, renal function, and vasoactive prostanoids in young and elderly subjects, marimjoudaenla, w2i0tSh drawal syndrome in the animal is it trieoanlsl y wOitKh tao nteakwe tthwiiss t,w i4t3h7 food? old interac- 985 Didanosine Drug development lack moifn biisoteeqrueidv alweintche coaf lcciipurmo-ffloorxtaicfiine d wheonra nagde- bioequivalence of two formulations of bioequivalence testing for locally acting gastroin- juice: a new twist on an old interaction, 461 testinal products: what role for gamma didanosine, encapsulated enteric-coated scintigraphy?, 1200 lack of effect of sucralfate on absorption and beads and buffered tablet, in healthy volun- pharmacokinetics of rosiglitazone, 670 teers and HIV-infected subjects, 791 evaluation of highly bound drugs: interspecies, intersubject, and related comparisons, 971 lack of interaction between amiodarone and effect of food on the oral bioavailability of mexiletine in cardiac arrhythmia patients, didanosine from encapsulated enteric- HIV testing in early clinical trials: who should 342 coated beads, 419 decide whether it is warranted?, 601 minimal interaction between gatifloxacin and Dietary fat absorption an introduction to clinical research and drug de- oxycodone, 928 velopment for pharmacy and pharmacology pharmacokinetic evaluation of possible interac- graduate students, 867 no effect of rosuvastatin on pharmacokinetics of tion between selected concomitant medica- digoxin in healthy volunteers, 1352 tions and orlistat at steady state in healthy the recruitment of normal healthy volunteers: a subjects, 1011 review of the literature on use of financial in- pharmacokinetic and pharmacodynamic assess- centives, 365 ments of HMG-CoA reductase inhibitors Diethylcarbamazine when coadministered with everolimus, 222 Drug interactions pharmacokinetics of diethylcarbamazine after pharmacokinetic and safety assessments of single oral dose at two different times of day carbamazepine decreases antihypertensive effect galantamine and risperidone after the two in human subjects, 327 of nilvadipine, 100 drugs are administered alone and together, Digoxin celecoxib does not affect the antiplatelet activity 1341 of aspirin in healthy volunteers, 1027 the effect of erythromycin and clarithromycin on pharmacokinetic evaluation of possible interac- pharmacokinetics of intravenous digoxin in differential influence of two cyclosporine formu- tion between selected concomitant medica- healthy volunteers, 1159 lations on everolimus pharmacokinetics: a tions and orlistat at steady state in healthy clinically relevant pharmacokinetic interac- subjects, 1011 no edffiegcot xionf rions uhveaaslttahtyi n voolnu ntpehearrsm, ac1o3k5i2n etics of tion, 95 plasminogen activator inhibitor-1: physiologic the effect of erythromycin and clarithromycin on role, regulation, and influence of common Dopamine pharmacokinetics of intravenous digoxin in pharmacologic agents, 1187 the influence of hormones and pharmaceutical healthy volunteers, 1159 steady-state pharmacokinetics and tolerability of agents on DHEA and DHEA-S concentra- effect of estrogen treatment and vitamin D status modafinil administered alone or in combina- tions: a review of clinical studies, 247 on differing bioavailabilities of calcium car- tion with dextroamphetamine in healthy vol- dOTC bonate and calcium citrate, 1251 unteers, 450 effect of food on the pharmacokinetics of (-) and effect of modafinil at steady state on the single- a study of the interaction potential of (+) dOTC when administered as an oral dose pharmacokinetic profile of warfarin in azithromycin and clarithromycin with racemate, 658 healthy volunteers, 205 atorvastatin in healthy volunteers, 444 Drug metabolism increased sensitivity to warfarin in elderly Erythromycin absolute bioavailability, pharmacokinetics, and panics, 145 the effect of erythromycin and clarithromycin on urinary excretion of the novel antimigraine Electrocardiogram pharmacokinetics of intravenous digoxin in agent almotriptan in healthy male volun- healthy volunteers, 1159 effects of azimilide on heart rate and ECG con- teers, 1303 duction intervals during sinus rhythm in pa- Estradiol bioavailability and metabolism of mometasone tients with a history of atrial fibrillation, 388 an evaluation of bioequivalence of two 7-day furoate: pharmacology vs methodology, 383 electrocardiographic effects of rivastigmine, 558 17B-estradiol transdermal delivery systems concordance between tramadol and by anatomical site, 1134 dextromethorphan parent/metabolite ratios: Electroencephalography oral hormone replacement therapy: factors that the influence of CYP2D6 and non-CYP2D6 effect of fluconazole on the pharmacokinetics influence the estradiol concentrations pathways on biotransformation, 24 and pharmacodynamics of oral and rectal achieved in a multiracial study population, effect of potent CYP2D6 inhibition by paroxetine bremazepam: an application of electroen- on atomoxetine pharmacokinetics, 1219 cephalography as the pharmacodynamic 137 method, 183 Estrogens effect of seville orange juice and grapefruit juice on indinavir pharmacokinetics, 1165 Elephantiasis effect of estrogen treatment and vitamin D status on differing bioavailabilities of calcium car- effect of terbinafine on pharmacokinetics and pharmacokinetics of diethylcarbamazine after bonate and calcium citrate, 1251 pharmacodynamics of desipramine in single oral dose at two different times of day healthy volunteers identified as cytochrome in human subjects, 327 evaluation of single- and multiple-dose P450 2D6 (CYP2D6) extensive metabolizers, Eletriptan epshtarromgaecnso ki(nCeetneisctsi n’ of tasbylenttsh)e:t iac slcoown-jrueglaetaesde 1211 the effects of concomitant administration of the pharmacaondk saifetny oef stingile cescsala t- estrogen replacement product, 332 theophylline and toborinone’ on ing oral doses of eletriptan, 520 plasminogen activator inhibitor-1: physiologic pharmacokinetics of both compounds in pharmacokinetics, pharmacodynamics, and role, regulation, and influence of common poor and extensive metabolizers via safety of the 5-HT1B/1D agonist eletriptan pharmacologic agents, 1187 CYP2D6, 492 following intravenous and oral administra- short-term effects of new synthetic conjugated influence of food intake and formulation on the tion, 528 estrogens on biochemical markers of bone pharmacokinetics and metabolism of Enalapril turnover, 290 bosentan, a dual endothelin receptor antagoo - a double-blind, placebo-controlled, dose-re- which studies of therapy merit credence? vita- nist, 283 sponse study of the effectiveness and safety min E and estrogen therapy as cautionary ex- lack of correlation between steady-state plasma of enalapril for children with hypertension, amples, 955 concentrations of haloperidol and 870 Ethics risperidone, 1083 Endocrine disruptors the recruitment of normal healthy volunteers: a pioglitazone: effect on CYP3A4 activity, 1299 endocrine disruptors: A new scientific role for review of the literature on use of financial in- sequential first-pass metabolism of nortilidine: clinical pharmacologists? impact on human centives, 365 the active metabolite of the synthetic opioid health, wildlife, and the environment, 7 Ethinyl estradiol drug tilidine, 1257 Endothelin receptor antagonists effect of rofecoxib on the pharmacokinetics of single plasma concentrations of 1’- hydroxymidazolam or the ratio of 1’- influence of food intake and formulation on the chronically administered oral contraceptives hydroxymidazolam:midazolam do not pre- pharmacokinetics and metabolism of in healthy female volunteers, 215 dict midazolam clearance in healthy sub- bosentan, a dual endothelin receptor antago- the influence of hormones and pharmaceutical jects, 1079 nist, 283 agents on DHEA and DHEA-S concentra- Ebastine Environmental issues tions: a review of clinical studies, 247 a double-blind, placebo-controlled study of effi- endocrine disruptors: A new scientific role for Everolimus cacy and safety of ebastine 20 mg once daily clinical pharmacologists? impact on human differential influence of two cyclosporine formu- given with and without food in treatment of health, wildlife, and the environment, 7 lations on everolimus pharmacokinetics: a seasonal allergic rhinitis, 1097 Epilepsy clinically relevant pharmacokinetic interac- Education tion, 95 clinical pharmacology: drugs as a benefit and/or advanced science education in the regulatory risk in sudden unexpected death in epi- pharmacokinetic and pharmacodynamic assess- arena: The Center for Drug Evaluation and lepsy?, 123 ments of HMG-CoA reductase inhibitors Research experience at the FDA, 711 when coadministered with everolimus, 222 multiple-dose, linear, dose-proportional development of innovative teaching materials: pharmacokinetics of retigabine in healthy Exercise-induced asthma clinical pharmacology problem-solving volunteers, 175 the new phosphodiesterase 4 inhibitor (CPPS) units: comparison with patient-ori- roflumilast is efficacious in exercise-induced ented problem-solving units and problem- pharmacoepidemiologic investigation of asthma and leads to suppression of LPS-stim- based learning, 477 clonazepam relative clearance by mixed-ef- ulated TNF-a ex vivo, 297 fect modeling using routine clinical educational issues in clinical pharmacology: pharmacokinetic data in Japanese patients, Fexofenadine who are our audiences and what are their 81 fexofenadine transport in Caco-2 cells: inhibition specialized needs?: understanding the role of veterinary medicine in public health, 718 Epinephrine with verapamil and ritonavir, 1269 an introduction to clinical research and drug de- the influence of hormones and pharmaceutical Fibrinolytic balance velopment for pharmacy and pharmacology agents on DHEA and DHEA-S concentra- plasminogen activator inhibitor-1: physiologic graduate students, 867 tions: a review of clinical studies, 247 role, regulation, and influence of common Elderly patients Eptifibatide pharmacologic agents, 1187 effects of celecoxib and diclofenac on blood pres- bleeding associated with eptifibatide targeting Fiduxosin sure, renal function, and vasoactive higher risk patients with acute coronary syn- single- and multiple-dose pharmacokinetics of prostanoids in young and elderly subjects, dromes: incidence and multivariate risk fac- fiduxosin under nonfasting conditions in 985 tors, 1366 healthy male subjects, 540

See more

The list of books you might like

Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.
DMCA & Copyright: Dear all, most of the website is community built, users are uploading hundred of books everyday, which makes really hard for us to identify copyrighted material, please contact us if you want any material removed.
Copyright @ PDFdrive.to, 2022 | We love our users